<SEC-DOCUMENT>0001193125-13-201065.txt : 20130506
<SEC-HEADER>0001193125-13-201065.hdr.sgml : 20130506
<ACCEPTANCE-DATETIME>20130506135032
ACCESSION NUMBER:		0001193125-13-201065
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20130506
DATE AS OF CHANGE:		20130506
EFFECTIVENESS DATE:		20130506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORASURE TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001116463
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				364370966
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16537
		FILM NUMBER:		13815392

	BUSINESS ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
		BUSINESS PHONE:		5036416115

	MAIL ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d532765ddefa14a.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Additional Materials</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549
</B></FONT></P> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>(Amendment No.
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U> ) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed by the Registrant <FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> &nbsp;&nbsp;Filed by a Party other than the
Registrant <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only&nbsp;(as permitted by Rule 14a-6(e)(2))</B> </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Additional Materials </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting Material Pursuant to &#167;240.14a-12 </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>OraSure Technologies, Inc. </B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Registrant as
Specified In Its Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>&nbsp;&nbsp;</B></FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and
state how it was determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee paid previously with preliminary materials. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.
Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount Previously Paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filing Party: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date Filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:3%;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commencing May&nbsp;6, 2013, OraSure Technologies, Inc. sent the following communication to certain
stockholders: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;6, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Re:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">OraSure Technologies, Inc. (&#147;OraSure&#148; or the &#147;Company&#148;) <BR>2013 Annual Meeting of Stockholders &#150; Supplemental <BR>Information Regarding the
Advisory Vote to Approve <BR><U>Compensation of the Company&#146;s Named Executive Officers</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Stockholder: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the 2013 Annual Meeting of Stockholders, the Company&#146;s stockholders will vote on a nonbinding proposal to approve the compensation of the
Company&#146;s named executive officers. <B>The Company requests that you vote FOR the proposal, as the Company&#146;s Board of Directors has unanimously recommended.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The proxy advisory firms of ISS Proxy Advisory Services (&#147;ISS&#148;) and Glass Lewis&nbsp;&amp; Co. (&#147;Glass Lewis&#148;) have recently issued reports recommending that our stockholders vote
against this proposal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As summarized below and described further in this letter and in the section entitled &#147;Executive
Compensation&#148; in the Company&#146;s 2013 Proxy Statement (the &#147;2013 Proxy Statement&#148;), we strongly disagree with ISS and Glass Lewis: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ISS and Glass Lewis largely ignore the significant strategic accomplishments by the Company (particularly the clinical development, FDA approval and
commercial launch of the OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> In-Home HIV test, the first and only product of its kind) which were
considered in determining the compensation paid to Douglas A. Michels, our CEO. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our long-term incentive equity awards are in fact performance-based, even though they vest with the passage of time. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The heavy reliance on total shareholder return (&#147;TSR&#148;) for one year is misleading. TSR should be compared to changes in
Mr.&nbsp;Michels&#146; realizable compensation to properly assess our pay-for-performance proposal. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our peer group consists of comparable companies in the medical diagnostics field and provides a reasonable source for benchmarking our compensation
program. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ISS and Glass Lewis ignore the actions we have recently taken to bring our compensation program more in line with best practices.
</FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Our Compensation Appropriately Reflects Our Strategic Achievements</U></B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ISS and Glass Lewis contend there is a misalignment between executive pay and performance based essentially upon the sole metric of total shareholder
return (&#147;TSR&#148;) generated by the Company during 2012. Their contentions, however, fail to fully recognize the significant strategic milestones achieved by the Company&#146;s management and the investment required to attain those milestones.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As explained in detail in our 2013 Proxy Statement, the three main components of our executive compensation are annual base salary, annual
incentive cash bonuses awarded under our Management Incentive Plan (&#147;MIP&#148;) and annual equity awarded under our Long-Term Incentive Plan (&#147;LTIP&#148;). Under applicable disclosure rules, the executive compensation described in our 2013
Proxy Statement reflects compensation awarded for management performance during both 2011 and 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Base salary levels
and equity awards received during 2012 were determined based on performance during 2011. The principal 2011 accomplishments underlying this compensation included the successful acquisition of DNA Genotek, Inc. (&#147;DNAG&#148;) for approximately US
$53 million, the successful completion of the final phase of clinical testing and submission to the U.S. Food and Drug Administration (&#147;FDA&#148;) of all modules to our pre-market authorization (&#147;PMA&#148;) application for the
Company&#146;s OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> In-Home HIV test, development of sales, advertising, manufacturing and logistic
strategies for commercializing the OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> In-Home HIV test, and receipt of PMA approval of a fingerstick
whole blood claim and a CLIA (Clinical Laboratory Improvement Amendments of 1988) waiver for the OraQuick HCV test. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Incentive cash bonuses reported in the 2013 Proxy Statement were made under the 2012 MIP and were based on performance during 2012.
The overriding strategic achievement affecting MIP bonus pool funding and individual awards was the receipt of FDA approval of the OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> In-Home HIV test in 2012, the first HIV in-home test of its type. Other significant factors considered by our Board of Directors (the &#147;Board&#148;) and the
Compensation Committee in determining the 2012 bonus pool included the successful commercial launch of the
OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> In-Home HIV test and the addition of $14.3 million in revenue from the first full year of operation by
DNAG. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">By any measure, these strategic accomplishments were significant. The OraQuick<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> In-Home HIV test is the first rapid infectious disease test and the only rapid HIV test that has ever been approved
by the FDA for use by consumers. We believe this product will have a significant impact on public health by expanding the opportunities for individuals to be tested and learn their HIV status. Similarly, the OraQuick<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> HCV test is the first and only rapid hepatitis C test to receive FDA approval in professional settings. In light of
the recommendations of the Centers for Disease Control and Prevention that baby boomers (who total approximately 80 million) get tested for HCV due to higher risk factors, we believe this product can also provide significant health benefits.
Finally, the DNAG acquisition in August 2011 represented our most significant strategic transaction since OraSure was formed in 2000 and represents an important entr&eacute;e into the molecular diagnostics market. All three accomplishments represent
potentially significant revenue opportunities for the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Not surprisingly, during the past several years the Company&#146;s financial position
has been negatively impacted, by the cost of these strategic projects. For example, we have spent $16.9 million and $19.4 million for the extensive clinical programs required to gain approval of the OraQuick<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> In-Home HIV test and OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> HCV test, respectively. These programs have significantly impacted our short-term financial performance. In addition, the Company&#146;s base business, which consists
principally of its OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> professional products, has been and continues to be negatively affected by economic
and competitive conditions which are unrelated to management performance. As has been widely reported and disclosed in the Company&#146;s SEC filings, the difficult economic climate has significantly impacted many of our customers&#146; ability to
purchase products, particularly in the public health market which heavily relies on state and local government funding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In reaching the
compensation decisions reported in our 2013 Proxy Statement, the Board and Compensation Committee chose to reward management for the significant strategic achievements described above and decided that management should not be unduly penalized for
the Company&#146;s short-term financial performance. We believe those compensation decisions were entirely appropriate and are consistent with the long-term interests of the Company and its stockholders. The ISS and Glass Lewis recommendations
appear to ignore the importance of these strategic achievements and, for this reason alone, should be rejected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>The Company&#146;s
Executive Compensation is Performance-Based </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ISS and Glass Lewis reports assert that the Company&#146;s executive compensation is
not sufficiently performance-based and, in particular, criticize the incentive equity awards made to executives because they utilize time-vesting. We strongly disagree with these criticisms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As explained in our 2013 Proxy Statement, equity awards under the LTIP are made on the basis of a number of factors, including the executive&#146;s individual performance against previously established
objectives for the applicable year. Dollar target ranges for the awards have been established for our CEO and the other named executive officers (&#147;NEOs&#148;) based on an assessment of equity awards at comparable medical diagnostic companies.
If an executive fails to achieve at least a &#147;Meets Expectations&#148; performance rating, that executive would not be eligible for an equity award except in the sole discretion of the Board or Compensation Committee. Thus, whether an executive
receives any equity award for a given year is based on prior year performance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, we have historically granted a combination of both
stock options and restricted shares to management. Awards currently are made 60% in stock options and 40% in restricted shares. The ISS and Glass Lewis reports fail to recognize that stock options, by their nature, are performance-based. An
executive receiving a stock option </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
will not realize any value or compensation from the award unless the market value of the Company&#146;s common stock rises above the exercise price. Compensation to our executives through the use
of stock options is clearly tied to the performance of the Company and the value we deliver to our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board and Compensation
Committee have decided to also include restricted shares as part of the annual equity awards. The Board and Compensation Committee believe that retaining qualified executives is an important goal of our compensation program and that regular awards
of restricted shares, with time-based vesting, strike an appropriate balance between retention and providing additional long-term performance incentives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the past several years, the mix of restricted shares and stock options awarded to executives has shifted from 40 percent stock options and 60 percent restricted shares to 60 percent stock options
and 40 percent restricted stock. The purpose of this shift is to make the overall equity award even more performance-based. In addition, these awards vest over a three to four year period, thereby further aligning the interests of our executives
with those of our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Significantly, despite their criticisms, neither ISS nor Glass Lewis discussed the cash
bonuses awarded for 2012 performance. As explained in our 2013 Proxy Statement, funding under the 2012 MIP was dependent on whether the Company achieved specific financial targets for consolidated revenues and operating performance objectives for
2012, along with certain business objectives related to the commercialization of the OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> In-Home HIV test
and expanding sales of the OraQuick<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> HCV test. Because the Company did not meet the threshold performance levels
for consolidated revenues or operating performance, no bonus pool funding was provided for either objective. These financial objectives accounted for 60% of the potential bonus pool funding for 2012. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>The Use of Total Stockholder Return (TSR) by ISS and Glass Lewis is Misleading </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In criticizing the Company&#146;s performance, both ISS and Glass Lewis provide measures of TSR over one, three and five-year periods ending December&nbsp;31, 2012. However, the use of TSR in this manner,
especially for a one-year period, is misleading and creates a mismatch of data. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As explained previously, the compensation reported in our
2013 Proxy Statement includes equity awards based on 2011 performance and cash bonuses based on 2012 performance, as required under the proxy disclosure rules. During 2011, our stock price rose from $6.01 on January&nbsp;3, 2011 to $9.11 on
December&nbsp;30, 2011, the last trading day of the year. This represents a positive return to stockholders of more than 58%. The equity awards received in 2012 by Mr.&nbsp;Michels and the other NEOs occurred in January 2012, or immediately after a
year in which the value delivered to our stockholders significantly increased. By relying so heavily on TSR for 2012, the ISS and Glass Lewis reports mismatch TSR data with performance unrelated to the equity awards made during 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">More importantly, the reliance on one-year TSR without adjusting Mr.&nbsp;Michels&#146; compensation results
in further inconsistency. TSR reflects the change in our stock price over a defined measurement period and represents the return to stockholders as if they liquidated their holdings at the end of that period, i.e. December&nbsp;31, 2012. However,
the equity awards criticized by ISS and Glass Lewis are valued based on our stock price on the grant date, which occurred earlier in 2012. No adjustments are made to the value of the equity awards to reflect subsequent changes in our stock price. In
effect, ISS and Glass Lewis allow the stock price to fluctuate for purposes of TSR but not when measuring the compensation paid to our executives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A more appropriate assessment of pay-for-performance would be to compare TSR to the &#147;realizable&#148; value of the compensation paid to executives. In so doing, the value of equity awards would be
determined based upon their intrinsic value at the end of 2012 as is the case when calculating TSR. The following table compares TSR for each of the years 2010, 2011 and 2012 with the realizable compensation paid to Mr.&nbsp;Michels for each of
those periods. Realizable compensation for each year includes (i)&nbsp;Mr.&nbsp;Michels&#146; actual base salary and any cash bonuses received during that year as reported in our 2013 Proxy Statement, (ii)&nbsp;the value of restricted shares
received during the applicable year valued at the $7.18 closing price of our stock on December&nbsp;31, 2012, and (iii)&nbsp;the &#147;in-the-money&#148; value of stock option awards received during the year. The &#147;in-the-money&#148; value
represents the difference between the $7.18 closing price of our stock on December&nbsp;31, 2012 and the exercise price for such option, multiplied by the number of shares subject to the option awarded to Mr.&nbsp;Michels. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g532765g03w45.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As shown in the above table, Mr.&nbsp;Michels&#146; realizable compensation of approximately $1.6 million in
2011 was reduced to approximately $1.0 million in 2012, or by 37%, which exceeds the reduction in TSR over the same period. Because the options granted to Mr.&nbsp;Michels in 2012 had an exercise price in excess of the closing price of our stock on
December&nbsp;31, 2012, Mr.&nbsp;Michels 2012 options had no realizable value as of year end. Consequently, Mr.&nbsp;Michels&#146; realizable compensation for 2012 was significantly lower than the level reported in our 2013 Proxy Statement because
of changes to our stock price, consistent with the reduction in TSR. We believe the foregoing table provides a more accurate description of our pay-for-performance. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Certain Other ISS Criticisms Are Without Merit </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ISS asserts that the Company
provided no rationale for its decision earlier this year to increase Mr.&nbsp;Michels&#146; equity award targets under the LTIP for performance beginning in 2013. This simply is not true. As described in the Company&#146;s Current Report on Form 8-K
filed April&nbsp;4, 2013, that change was adopted to align Mr.&nbsp;Michels&#146; targets &#147;more closely with compensation levels at comparable medical diagnostics and healthcare companies,&#148; based on advice and data from the Company&#146;s
peer group of companies provided by the independent compensation consultant (Pearl Meyer&nbsp;&amp; Partners) engaged by the Compensation Committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ISS also criticizes the peer companies selected by the Company because of the &#147;presence of multiple outsized peers exceeding two times the company&#146;s revenue . . .&#148; This criticism is also
unwarranted for the simple reason that we often must recruit from larger companies in order to obtain executives with the skill sets and experience required by our business. The Company&#146;s peer group is in fact more closely aligned with OraSure
and useful for benchmarking purposes than the groups used by ISS and Glass Lewis because it predominantly consists of other medical diagnostics companies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Other Relevant Factors </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finally, we believe the following additional features of our
compensation program should be considered in evaluating our say-on-pay proposal, none of which seems to have been seriously considered by ISS or Glass Lewis: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted a &#147;value transfer&#148; methodology under which long-term incentive equity awards are targeted at market-based dollar values
rather than absolute numbers of restricted stock or option shares. This approach avoids volatility in the value of equity awards resulting from short-term movements in the price of our Common Stock and better aligns the Company&#146;s practices with
industry standards. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board and Compensation Committee regularly utilize independent compensation consultants to provide compensation advice, including competitive
assessments of our program compared to compensation paid to executives at a peer group of comparable medical diagnostic and healthcare companies. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board recently adopted a compensation recoupment or &#147;clawback&#148; policy, under which the Board or Compensation Committee may recover excess
compensation paid to our executives if our financial statements are restated due to misconduct by that executive. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Messrs. Michels and Spair, and each non-employee member of the Board, are subject to stock ownership guidelines, measured as a multiple of annual base
salary or cash fees, as applicable. In addition, each of these individuals is required to retain 25% of the shares received upon the vesting of restricted shares or the exercise of stock options until that individual complies with the applicable
ownership multiple. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Stock Award Plan, under which LTIP equity awards are made to executives and Board members, was recently amended to prohibit both the repricing and
repurchase of under-water stock options or other equity awards without stockholder approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company does not provide its executives with any perquisites that are not offered to all employees of the Company. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We regularly assess the risks associated with our compensation programs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe the foregoing features help bring our compensation program in line with current best practices and should be considered in evaluating whether to approve our executive compensation as disclosed
in the 2013 Proxy Statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Conclusion </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the reasons set forth above, and in further detail in our 2013 Proxy Statement, we request that our stockholders reject the recommendations contained in the ISS and Glass reports and that they vote
<B>FOR</B> the proposal to approve the compensation of the Company&#146;s named executive officers. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely, </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">OraSure Technologies, Inc. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g532765g03w45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532765g03w45.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`:\"D`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`SO$#2IX<U-H;M[.46TA2X2(R-$=IP
MP4`EL=<#DT`>.:'XG@ETG0-.BU:XM-3-UY<<LFJN;65%9&DFW/@R9R8Q&<C<
M6&,@D`'6>+-8E3Q/8W&DZQ]KE\M$ATR(S+YFYF!F5DD"2;>-RE7P$[9H`Y.Z
MU[44T>Z:VUN_>S6%WM[@W+[VOA;1LL(;JV9"_P"[Y&X;<<;0`=1XGUV\;7--
M^Q:BP?\`T9;:.WG.V>;[3LN490</M0<@YV\GC&0`<K:Z_JCV\(N=9O4L7$+:
MA.+I\PWA@N&>+=G,?[U81Y8P,D#'S8(![+I]Q=CPY:W-S;R2WOV57DA3:'>3
M8"5&X@`D\<D#W%`&=IWBFXU&[O+9/#6JPO9R"*8R/;85RB.%XF.?E=3GISUS
MQ0!I?VC=?]`:]_[[A_\`CE`!_:-U_P!`:]_[[A_^.4`']HW7_0&O?^^X?_CE
M`!_:-U_T!KW_`+[A_P#CE`!_:-U_T!KW_ON'_P".4`']HW7_`$!KW_ON'_XY
M0`?VC=?]`:]_[[A_^.4`']HW7_0&O?\`ON'_`..4`']HW7_0&O?^^X?_`(Y0
M`?VC=?\`0&O?^^X?_CE`!_:-U_T!KW_ON'_XY0`?VC=?]`:]_P"^X?\`XY0`
M?VC=?]`:]_[[A_\`CE`!_:-U_P!`:]_[[A_^.4`']HW7_0&O?^^X?_CE`!_:
M-U_T!KW_`+[A_P#CE`!_:-U_T!KW_ON'_P".4`']HW7_`$!KW_ON'_XY0`?V
MC=?]`:]_[[A_^.4`']HW7_0&O?\`ON'_`..4`']HW7_0&O?^^X?_`(Y0`?VC
M=?\`0&O?^^X?_CE`!_:-U_T!KW_ON'_XY0`?VC=?]`:]_P"^X?\`XY0`?VC=
M?]`:]_[[A_\`CE`!_:-U_P!`:]_[[A_^.4`']HW7_0&O?^^X?_CE`!_:-U_T
M!KW_`+[A_P#CE`!_:-U_T!KW_ON'_P".4`']HW7_`$!KW_ON'_XY0`?VC=?]
M`:]_[[A_^.4`']HW7_0&O?\`ON'_`..4`']HW7_0&O?^^X?_`(Y0`?VC=?\`
M0&O?^^X?_CE`!_:-U_T!KW_ON'_XY0`?VC=?]`:]_P"^X?\`XY0`?VC=?]`:
M]_[[A_\`CE`!_:-U_P!`:]_[[A_^.4`']HW7_0&O?^^X?_CE`!_:-U_T!KW_
M`+[A_P#CE`!_:-U_T!KW_ON'_P".4`']HW7_`$!KW_ON'_XY0`?VC=?]`:]_
M[[A_^.4`']HW7_0&O?\`ON'_`..4`']HW7_0&O?^^X?_`(Y0`?VC=?\`0&O?
M^^X?_CE`!_:-U_T!KW_ON'_XY0`?VC=?]`:]_P"^X?\`XY0`?VC=?]`:]_[[
MA_\`CE`!_:-U_P!`:]_[[A_^.4`']HW7_0&O?^^X?_CE`!_:-U_T!KW_`+[A
M_P#CE`!_:-U_T!KW_ON'_P".4`']HW7_`$!KW_ON'_XY0`?VC=?]`:]_[[A_
M^.4`']HW7_0&O?\`ON'_`..4`']HW7_0&O?^^X?_`(Y0`?VC=?\`0&O?^^X?
M_CE`!_:-U_T!KW_ON'_XY0`?VC=?]`:]_P"^X?\`XY0`?VC=?]`:]_[[A_\`
MCE`!_:-U_P!`:]_[[A_^.4`']HW7_0&O?^^X?_CE`!_:-U_T!KW_`+[A_P#C
ME`#9-3NTC9ET.^<J"0JO!EO89D`_.@"KHOB*36+^]M&T/4+$V3>7-)<M`5#[
M4<(-DC$G;(ISC'OGB@#RRY\0:J/$>K0OJUZEK]K*79%PX-O;B\C4LRY_T?$1
M8*RGYURYP0*`+MQ>>);:PMM0^WW$]O=V<B>6+F02>2C9,F.`IV``2@ELRKD8
M6@#U/1-1_M?1+/4/+5/M$8?"2>8O_`6P-P[@X&1@T`7Z`"@`H`*`"@`H`;'&
MD2!(T5$'15&`*`&PP16T*PP1)%$@PJ(H4`>P%`$E`$<,$5O'Y<$21)DMM10!
MDG).!ZDDT`24`%`'/^'O^0YXL_["B?\`I';4`=!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`<_X>_Y#GBS_L*)_P"D=M0!T%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`<OX>2\_X2SQ8_GP_8?MZ#R?)/F>9]DMOFW[L;<<;=N<\Y[4`=10`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`<_X>_Y#GBS_`+"B?^D=M0!T%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`<_P"'O^0YXL_["B?^D=M0!T%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0!S_`(>_Y#GBS_L*)_Z1VU`'04`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0!R_AZSB_X2SQ9?;YO.^WI%M\]_+V_9+8Y\O.S=_M8
MSCC.*`.HH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`.?\/?\ASQ9_V%$_\`2.VH
M`Z"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`.7\/7]G_P`)9XLT[[7#]N^W
MI-]G\P>9Y?V2V&_;UVYXSTS0!U%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!S_
M`(>_Y#GBS_L*)_Z1VU`%>X\<V$$ER!8W\L<,OV>.:.)3'<3>:(O*1MV`V]@/
MFVCJ02`2`"%?B)H[/L6"[+&#S$&U!YC[E7R1EO\`6;F4<X&6Z]<`'7#ITQ0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0!S_A[_D.>+/\`L*)_Z1VU`'04`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`9.L>(;+2%\IF,U\X/DVL2[Y)#V^4=![G`K*I5C#3KV.["8&KB?>6D%O)Z
M)?,Y+P5XA\1G6I['Q4LD'GY^R^=!Y89QU52``>#[]*YL/5J\SC5^1[N;X'!*
MA&K@-;?%9WTZ-]CT.NX^4"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`\Y@^,6E7-O'/%H&LM'(H=3MMQD$9'_+:IYDCFEBZ,6TW^9)_P`+<T[_`*%[
M6?RM_P#X]1S(GZY0_F_!A_PMS3O^A>UG\K?_`./4<R#ZY0_F_!G2^%O%-KXK
ML;FZM;6ZM1;3FW>.Y"!MVQ7R-K,,8<=Z:=SHA.,X\T=C=IEA0`4`%`!0`4`%
M`!0`4`1SPK<6\L#EPDBE&,;LC`$8X92"I]P010!R?A#1K73_`!!XIDAEO79+
M]8@)[Z:8;3:V[9(=B"V3]X\XXSCB@#.E^%\?]KW>H6VHQV[O.;F`+:Y(E\])
M\RG=^]`="`/EPK,,]Z`+MS\.;&YTVUM6F19H8I%>Y6`"25VW$$D'.P%W.PY&
M2#D8H`Z71--_L?1;33O,1_L\83*1[%_X"N3M7T&3@8%`%^@`H`*`"@`H`*`"
M@`H`*`"@`H`*`.7\/7$O_"6>++;[%-Y/V])/M64\O=]DMALQNW[N_P!W&.^>
M*`.HH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`*>I:M8Z/:FXO[E((^@SU8^@`Y)]A43G&"O)G1A\-5Q,^2E&[_
M`*W[&']HU_Q"<6D;:+IQ_P"6\J@W,@_V4Z(#ZGGVK&]2IM[J_$]+V>#P7\1^
MUGV7PKU?7Y:>9JZ3H&G:*K&TA)FD_P!9/(V^60^K,>36L*<8;'#BL;6Q37M'
MHMDM$O1$^J:7:ZO8O:7:;HVY!!PR,.C*>Q'K3G!35F9X?$5,-452F]?S\GY&
M/INKW6F:C'HFN/F5^+2]Z+<@=CZ./3OVK*$W&7)/Y/O_`,$[\1A:=>D\5A=E
M\4>L?3O'\CI*Z#R`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^9]$_Y`
M&G?]>T?_`*"*P>Y\U7_BR]67J1D%`'I'PC_Y!&N_]A0_^D\%;1V/?P?\"/S_
M`#/0JHZPH`*`"@`H`*`"@`H`*`"@#G_#W_(<\6?]A1/_`$CMJ`.@H`*`"@`H
M`*`"@`H`*`&NZQHSNP5%&2Q.`!ZT`9=KXIT"]AM9K;6K&2.Z<QP$7"_O6'55
MYY/L*`+LNH64%[#92WD$=W,I:.!I`'<#J0O4@>U`%8>(=$-LMR-8L?(:7R%D
M^TIM,G]P'.-WMUH`LW&HV-I=6]M<WD$-Q<DK#%)(%:4CJ%!Y/X4`5O\`A(M$
M%O-<?VQ8>3!+Y$LGVE-L<G38QSPWL>:`-($$`@Y%`'/^'O\`D.>+/^PHG_I'
M;4`=!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`$=Q<0VD#SW$R0PH,L[L%51[DTFU%79<*<JDE""NWT1SC:_J.N,8O#
M=J!!T.HW2D1?\`7J_P!>!6'M)3TIKYL]98*AA%S8V6O\D=_F]E^9<TSPQ:V5
MS]NNY9-1U(CFZN3DK[(O1!]*J%%1?,]7W.?$9A4JP]E32A#^5?J]W\S;K8\X
M*`"@"EJNE6FLV$EG>1[XFY!'#(1T8'L1ZU$X*:Y6=&&Q-3"U%4IO7\_)^1C:
M5JMWI5_'H6NR;Y6XL[TC"W(_NGT<>G>LH3<'R3^3[_\`!/0Q.&IXBF\5A5I]
MJ/\`+YK^[^1TU=!XX4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!\SZ)_P`@
M#3O^O:/_`-!%8/<^:K_Q9>K+U(R"@#TCX1_\@C7?^PH?_2>"MH['OX/^!'Y_
MF>A51UA0`4`%`!0`4`%`!0`4`%`'/^'O^0YXL_["B?\`I';4`=!0`4`%`!0`
M4`%`!0`4`9^NV0U'P_J-B;9;H7%O)%Y#2F,294C;O`.W/3..*`/+])T;Q;)I
MFDZ;J6A7#6"S@O<`VWVJ.W1D9(6.Y1@R*6++D[0.,G@`V-7T'5]>U^2^MK*:
M"WOX[4K-,51[7R6FW!ESN^;S!C&>^<=P#%NO!?B*XL+QTT<1-<VCV`M1/%\K
M-;1Q"<G.-H*'H2VT],\``W-:T75]=O[6:VL+A8G^S0,\Y1#;FWNO,:3!.XAU
M7Y<9)PN0*`,&T\$^)+?['</I;2_888K-K<S1YN"MO<1&9?FQM)G4_-AL`\9P
M"`>J6%G=67AVULEFC%Y#:K$)74NH<(!N(R"1GG&1GU%`'/\`A"'6(_$'BDW]
M]93QB_4.L%F\1,GV6WPP)D;"[<#;@G/.>U`'84`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`!.!D\"@#G+GQ2+BY>Q\/VIU2[
M0X=U;;!"?]J3IGV&36#K7?+35W^!ZU/+>2*JXN7LX]/YGZ+]79!;^&'NYTN_
M$5W_`&E<*<I`%VV\1_V4[GW;/X4E1N[U'?\`()YBJ473P<>1=]Y/U?3T5CH@
M`H````X`':N@\G<\0O?%WBIM7U18O$=S!%%?W,,<:6]N0B),ZJ,M&2>%'4FL
MW)IV/+Q&,J4JC@DB'_A+/%O_`$--Y_X#6O\`\:I<[,?[0J]E_7S#_A+/%O\`
MT--Y_P"`UK_\:HYV']H5>R_KYGH/PSUG5-8TC5&U6^>]EM[\PQR/&B$)Y,38
MPBJ.KMVK1.Z/3P]1U::FSM:9N5-2TVUU:QDL[R+?"_X%3V(/8CUJ9P4U9F^'
MQ%3#5%4INS7]?<8^FZE=:3?1Z+K4F]GXL[T\"X']UO1Q^O6L83<'R3^3[_\`
M!._$8>GB*;Q.&5K?%'^7S7]W\CHZZ#R0H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`/F?1/^0!IW_7M'_Z"*P>Y\U7_BR]67J1D%`'I'PC_P"01KO_`&%#_P"D
M\%;1V/?P?\"/S_,]"JCK"@`H`*`"@`H`*`"@`H`*`.?\/?\`(<\6?]A1/_2.
MVH`Z"@`H`*`"@`H`*`"@#%C\1Q3:NUC!I]]-"DOD/>1QJ84D`R5/S;N.[;=H
M/&<T`;5`!0`4`%`!0`4`%`'/^'O^0YXL_P"PHG_I';4`=!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&+JGB:STZY%E"DE]J3#
M*VEL-S_5NRCW-8SJQB^5:OL>CALOJUH^UDU"'\ST7R[OT*0T35-=^?Q%<"&U
M/33K5R%^DC]7^@P/K4^SG4_B/3LOU.CZYA\'I@XWE_/+?_MU=/5W9T5M:P65
MNEO:PI#"@PJ(H``^E;I**LCR:E2=63G-W;[DM,@*`/GBY_Y"^L?]A2\_]*)*
MQEN?/XS^/+Y?D,J3E"@#TCX1_P#((UW_`+"A_P#2>"MH['OX/^!'Y_F>A51U
MA0!4U+3;75K&2SO(M\+_`(%3V(/8CUJ9P4U9F^'Q%3#5%4INS7]?<8>G:K>:
M-J,>BZ[+Y@E.+*^(P)A_<?T?^=8QFX2Y)_)_UU/2KX:GBJ3Q.%5K?%'MYK^[
M^1T]=!XP4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?,^B?\@#3O^O:/_P!!%8/<
M^:K_`,67JR]2,@H`](^$?_((UW_L*'_TG@K:.Q[^#_@1^?YGH54=84`%`!0`
M4`%`!0`4`%`!0!S_`(>_Y#GBS_L*)_Z1VU`'04`%`!0`4`%`!0`4`8-KH5_8
MZM-)::JL6FSW!N9+;[,#(7;[P$A;`4GG&W/^U0!O4`%`!0`4`%`!0`4`<OX>
MLXO^$L\67V^;SOMZ1;?/?R]OV2V.?+SLW?[6,XXSB@#J*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`,[5M=T_1(E:]G"NYQ'$@+22'T
M51R:SG4C#XCKPV#K8IVI+1;O9+U>QD>7K_B(?OB^B::P^XC`W4@]STC_``R?
MI65JE3?W5^/_``#NYL'@OA_>S_\`)%^LOP1M:7H]AHUN8;"V2%2<LPY9SZLQ
MY)]S6T*<8*T4>?B,56Q4N:K*_P"2]%T+U6<P4`%`!0!\\7/_`"%]8_["EY_Z
M425C+<^?QG\>7R_(94G*%`'I'PC_`.01KO\`V%#_`.D\%;1V/?P?\"/S_,]"
MJCK"@`H`J:GIEIJ]A+97L0DAD'(Z$'L0>Q'K4S@IKED;X?$5,-456D[-&%IF
MHWFAWT>BZY*9$<[;*_;I-Z(_H_\`.L(2E3?)/Y/^NIZ6(H4L53>)PJLU\4>W
MFO[OY'45TGC!0`4`%`!0`4`%`!0`4`%`!0`4`%`'S/HG_(`T[_KVC_\`016#
MW/FJ_P#%EZLO4C(*`/2/A'_R"-=_["A_])X*VCL>_@_X$?G^9Z%5'6%`!0`4
M`%`!0`4`%`!0!'.9EMY6MXTDG"DQI(Y16;'`+`$@9[X./0T`<GX0FUB3Q!XI
M%_8V4$9OU+M!>/*1)]EM\*`8URNW!W9!SQCO0!R&M^)]4F\4:I')/J5AIX-M
M&Z-#+`(+<7>R67S.`-R9.]3PO?*G``RXO/$MM86VH?;[B>WN[.1/+%S()/)1
MLF3'`4[``)02V95R,+0!ZGHFH_VOHEGJ'EJGVB,/A)/,7_@+8&X=P<#(P:`+
M]`!0`4`%`'#:/J.MZAXUU>*2;57T^SU`P((5M!:HHAC;:^X><3ECROJ/>@#N
M:`"@`H`*`"@`H`*`.7\/7]G_`,)9XLT[[7#]N^WI-]G\P>9Y?V2V&_;UVYXS
MTS0!U%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!7OK^TTRT
M>ZO;B.W@3J\C8%3*2BKR9K1HU*\U3I1;?D<__:FL^(05T6`Z?8L/^/\`ND^=
MQZQQGG\6P/:L.>=3X-%W?Z(]3ZMA<%KB7SS_`)8O1?XI?HOO-'2?#EAI4K7*
MA[F_D'[R[N&WRM^)Z#V&!6D*48._7N<N)Q];$14'[L%M%:+_`(/J]37K4X`H
M`*`"@`H`*`/GBY_Y"^L?]A2\_P#2B2L9;GS^,_CR^7Y#*DY0H`](^$?_`""-
M=_["A_\`2>"MH['OX/\`@1^?YGH54=84`%`!0!5U#3K75;&6RO81+!(,,I_0
M@]B/6IE%37*S:A7J8>HJE)V:,/3M0NM#OHM%UJ4RQR';97S?\M?^F;^CC_Q[
MZUC&3IODG\G_`%U/2KT*>+IO$X96:^*/;S7]W\O0Z:N@\<*`"@`H`*`"@`H`
M*`"@`H`*`"@#YGT3_D`:=_U[1_\`H(K![GS5?^++U9>I&04`>D?"/_D$:[_V
M%#_Z3P5M'8]_!_P(_/\`,]"JCK"@`H`*`"@`H`*`"@`H`*`.?\/?\ASQ9_V%
M$_\`2.VH`Z"@`H`*`"@`H`*`"@#E2_@Q_%18Z=9'61,%^V'3^?-QPOG[-N_'
M\.[-`'54`%`!0`4`%`!0`4`<_P"'O^0YXL_["B?^D=M0!T%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`-=TC1G=@B*,EF.`!1L-)R=D<W)XFGU61
M[;PS:B[(X:]ERMLA]CU<CT7\ZY_:N>E)7\^AZ\<OAATIXV7+_=7Q/Y=/G]Q-
M9>%HA=IJ&KW#ZIJ"\J\PQ'%_N)T7Z\GWIQHJ_--W9G6S&7(Z.'C[.'EN_5[O
M\O(Z"MSRPH`*`"@`H`*`"@`H`^>+G_D+ZQ_V%+S_`-*)*QEN?/XS^/+Y?D,J
M3E"@#TCX1_\`((UW_L*'_P!)X*VCL>_@_P"!'Y_F>A51UA0`4`%`!0!5U#3K
M75;&6RO81+!(,,I_0@]B/6IE%37*S:A7J8>HJE)V:.=T[4KSPYJ$6B:Y.TUM
M,VVQU!_^6GI'(>S^A_B^M<\9ND^2>W1_H_,]:OAZ>-IO%856DOBAV_O1\NZZ
M>AUE=1X84`%`!0`4`%`!0`4`%`!0`4`?,^B?\@#3O^O:/_T$5@]SYJO_`!9>
MK+U(R"@#TCX1_P#((UW_`+"A_P#2>"MH['OX/^!'Y_F>A51UA0`4`%`!0`4`
M%`!0`4`%`'/^'O\`D.>+/^PHG_I';4`=!0`4`%`!0`4`%`!0!Q'_``B&I9_L
MOS+7^Q_[4_M/S_,;[1GSO.\O9MQC?_%NSCC'>@#MZ`"@`H`*`"@`H`*`.7\/
M7$O_``EGBRV^Q3>3]O23[5E/+W?9+8;,;M^[O]W&.^>*`.HH`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`,&_P#%$$5V^GZ7`VIZDO6&$_+'_OOT4?K[
M5C*LD^6.K/3HY=.4%6KODAW>[]%N_P`O,KIX;NM7D6?Q-="Y4'*V$.5MT[C=
MW<CWX]JGV3GK5?RZ?\$U>/IX9<F"CR_WG\3].D?EKYG21QQPQK'$BI&HPJJ,
M`#T`K=*VB/(E)R=Y.['4Q!0`4`%`!0`4`%`!0`4`?/%S_P`A?6/^PI>?^E$E
M8RW/G\9_'E\OR&5)RA0!Z1\(_P#D$:[_`-A0_P#I/!6T=CW\'_`C\_S/0JHZ
MPH`*`"@`H`*`*NI:;::M82V-]"LUO*,,I_F/0^]3*"FN66QOA\14PU15:3LT
M<_IM]>>'+N+1]:G,]I(VRQOVZMZ1R>C^A_B^M80E*D^2>W1_HSU,11I8V#Q.
M%5I+64?_`&Z/EW73T.JKI/$"@`H`*`"@`H`*`"@`H`*`/F?1/^0!IW_7M'_Z
M"*P>Y\U7_BR]67J1D%`'I'PC_P"01KO_`&%#_P"D\%;1V/?P?\"/S_,]"JCK
M"@`H`*`"@`H`*`"@`H`*`.?\/?\`(<\6?]A1/_2.VH`Z"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`.?\/?\ASQ9_V%$_\`2.VH`Z"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`,K5O$-AI#+#(S37CC]W:P+OE?Z*.GU.!64ZL8:/?L=V
M&P-;$KFCI%;R>B7S_IF9_9VM^(>=5G.F:>?^7*V?]ZX_Z:2#I[A?SK/EJ5/C
MT7;_`()U^WPF"TPZYY_S-:+TC^K^XWK#3K/2K1;6PMH[>!>B(N!]?<^];QC&
M"M%'F5Z]7$3=2K)M^9:JC$*`"@`H`*`"@`H`*`"@`H`*`/GBY_Y"^L?]A2\_
M]*)*QEN?/XS^/+Y?D,J3E"@#TCX1_P#((UW_`+"A_P#2>"MH['OX/^!'Y_F>
MA51UA0`4`%`!0`4`%`%>^L;;4K*6SO(5EMY5VLC=ZF45)69K1K5*%15*;LT<
M_8W]SX<O(M(U>9I;.4[;*^<]?2.0_P![T/\`%]>N$9.D^2>W1_HSU*U&&-@\
M1AU:2^**_P#2H^7==/0ZBND\8*`"@`H`*`"@`H`*`"@#YGT3_D`:=_U[1_\`
MH(K![GS5?^++U9>I&04`>D?"/_D$:[_V%#_Z3P5M'8]_!_P(_/\`,]"JCK"@
M`H`*`"@`H`*`"@`H`*`.?\/?\ASQ9_V%$_\`2.VH`Z"@`H`*`"@`H`*`"@#*
M;Q)I2:N-+-RWVK>(^(7,8<C.PR8V!\<[<Y]J`-6@`H`*`"@`H`*`"@#E_#R7
MG_"6>+'\^'[#]O0>3Y)\SS/LEM\V_=C;CC;MSGG/:@#J*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`*6IZO8:-:_:+^Y2"/.%W'ECZ*.I/L*B<XP5Y,Z,/A:V)GR
M48W?Y>O8Q/M&O^(N+1'T733_`,MY5!N9!_LKT0'U//M6-ZE3;W5^)Z/)@\%_
M$?M9]E\*]7U^6GF:NDZ!I^BJ_P!DA)FD_P!;/(=\LA]68\FM84XPV.+$XVMB
MFO:/1;):)>B-.M#C"@`H`*`"@`H`*`"@`H`*`"@`H`*`/GBY_P"0OK'_`&%+
MS_THDK&6Y\_C/X\OE^0RI.4*`+WA:]UBV.KII^MW5C$;T$QPQ0L"WDQ<Y>-C
MGIWQQ7?AZ49PNS6IF%7"QA""5K7U]7YG0?VKXF_Z&S4/_`>U_P#C-;_5H&/]
MM8CLOQ_S#^U?$W_0V:A_X#VO_P`9H^K0#^VL1V7X_P"9T/@/5=7O-:UBSU+5
M)K^."WMI8C-'$A0NTP;_`%:+D?(O6N:K!0E9'MY?BIXJDYS2O>VGR.[K(]`*
M`"@`H`*`*]]8VVI64MG>0K+;RKM9&[U,HJ2LS6C6J4*BJ4W9HYNQOKGPO>Q:
M1J\S3:?*VRROG[>D4A]?0]ZPC)TGR3VZ/]&>O6HT\?3>(PZM-?%'_P!NCY=U
MT.LKI/#"@`H`*`"@`H`*`"@#YGT3_D`:=_U[1_\`H(K![GS5?^++U9>I&04`
M>D?"/_D$:[_V%#_Z3P5M'8]_!_P(_/\`,]"JCK"@`H`*`"@`H`*`"@`H`*`.
M?\/?\ASQ9_V%$_\`2.VH`R=2\>76EZS-I=QHBBX<H+-1=@E]\ZPH9<*?*#%]
MP^\2JMP",4`5?^%H0B8Q-IRHYMO,4/<X_>[PFUOE^5-Q/[SGA6./EH`[NVN8
M;RUBN;::.:"50Z21L&5P>A!'!'O0!+0`4`%`!0!SMAINM:7JMS%;_86TRYNF
MNGFD=_.7=RR!`,=>C;NG\)H`V-3U"WTG2KO4;MF6VM(6FE*KDA5&3Q]!0!A6
M'C>RNK/1I;FTN;2?5Y-EM`^QV(P3O)5B`N!W.?:@"?4O&.F:7XCM]#FW&ZEA
M\\D2Q*$3YN<,X9ONMP@8\4`9K_$G28[*2XDL=01HLO)"8TWI$(UD,I&[!38R
MG@EN<8SQ0!JZKXLT_2+ZUMITF<3^66EC"E(1(X2-GR0<,QP,`^^`,T`9,?Q+
MTB6$-'9WSRN5,,*HA>>)D=Q*OSXV;8I#R0WR],D`@'76UQ%>6L-S`VZ&9!(C
M>JD9!H`Q/#W_`"'/%G_843_TCMJ`.@H`*`"@`H`*`"@`H`*`"@`H`*`(KBX@
MM+=Y[B5(88QEG=@`H]R:3:BKLN%.522A!7;Z(YTZ]J.N9C\.6P6WS@ZA=*1'
M_P!LUZO]>!6'M)5-*:^;/66"H837&RU_DCO\WLOS+>F>&+2QN?MUU+)J&ID<
MW5R<L/9!T0>PJH45%\SU?<PQ&8U*L/94TH0_E7ZO=_,W*V/-"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`^>+G_D+ZQ_V%+S_`-*)*QEN?/XS^/+Y?D,J3E"@
M"WX9^]J__7X/_1,5>IA/X9R8W>'I^K-ZNLX`H`W?A[_R-.O_`/7G9_\`H=Q7
M#B?C/JLE_P!W?K^B/1*YCV@H`*`"@`H`*`*]]8VVI64MG>0K+;RKM9&[U,HJ
M2LS6C6J4*BJ4W9HYZRN[GPQ<PZ7JD[3Z=(0EG?/U4]HY#Z^C=ZPC)TGRRVZ/
M]&>K6I0Q\'7H*TUK**_]*C^JZ'4UTGBA0`4`%`!0`4`%`'S/HG_(`T[_`*]H
M_P#T$5@]SYJO_%EZLO4C(*`/2/A'_P`@C7?^PH?_`$G@K:.Q[^#_`($?G^9Z
M%5'6%`!0`4`%`!0`4`%`!0!'/!#=6\MO<1)-!*I22.10RNI&""#P01VH`Y/P
MAH6CZ9X@\4RV&E65I)'?K"C06Z(5C-K;L4!`X7<2V.F3F@!Q\`6CW.HSR:QJ
M3M?3K<G=Y.8I4<-&R-Y>[Y"H`4DKC.0:`+EQX+TNYTJTTV5IVM[5)`@++G>X
M(,A./O\`S-@]/F/%`&OIM@FEZ=!91R22K$N/,DQN<]23@`9)YX`'M0!;H`*`
M"@`H`Y9_&#KXGDTM=/!M(KN.Q><SXD\YXO,&(]O*;2/FW9SGC`S0!T5[`]U8
M7%O%.8))8V19556*$C&<,"#CT(Q0!Q_AOX?MH>D6=I)J$;20ZB+]A#!LBR$*
M;$3/R`]3UY)XYX`+FI^&-3\0I;1ZOJL2V@,<D]I!!QYB,6!20G<`>`P(;..-
MN30!D3?#&6XM)EEUL&ZGB:UDF^R`#[.T21%`N[AL1J=V2,_PXXH`T+SP7<ZM
M=6]Q>WL$)5HTGC@A)\V&&<RP*&+95AQN.#G)P!P:`,Z#X7O;)"\6LA;JU5(+
M:3[+E4@2*6((R[_F;;,_S9'.#MX((!V\&FPP:/'I:M(((X!;@K(R/M"[>&4@
M@X[@@B@#F_"&C6NG^(/%,D,MZ[)?K$!/?33#:;6W;)#L06R?O'G'&<<4`=A0
M`4`%`!0`4`%`!0`4`%`"$A5)/`'-`)7T/.W^+FE3%X;2)(9MVU)-0N([>'']
MXL3G_@(&:XXXKVCY::U/I*V0O!Q57%U$H^5V[]ET^=Q;?4O"-W<)>>(O&NC:
MG<(=R0_;HEMX3_LINY/NV36BHW=ZCN_P.*>8JE%T\''DCU?VGZOIZ*QT@\=>
M#U``\5:*`.@^WQ?_`!5=!Y&YH:9KNCZWYO\`9.JV5_Y./,^RW"2[,YQG:3C.
M#^1H`T*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^>+G_D+ZQ_V%+S_`-*)
M*QEN?/XS^/+Y?D,J3E"@"WX9^]J__7X/_1,5>IA/X9R8W>'I^K-ZNLX`H`W?
MA[_R-.O_`/7G9_\`H=Q7#B?C/JLE_P!W?K^B/1*YCV@H`*`"@`H`*`"@"&[M
M+>_M);6ZB66"5=KHPR"*4HJ2LS2E5G1FJE-V:.<M;V?PM<QZ;JLS2Z9(P2TO
M7Y*'M'(?7T;OWKG4G2?++;H_T9ZU2C#,(.M05IKXH]_[T?U70ZFND\4*`"@`
MH`*`"@#YGT3_`)`&G?\`7M'_`.@BL'N?-5_XLO5EZD9!0!Z1\(_^01KO_84/
M_I/!6T=CW\'_``(_/\ST*J.L*`"@`H`*`"@`H`*`"@`H`Y_P]_R'/%G_`&%$
M_P#2.VH`Z"@`H`*`"@`H`*`"@"HVE:<VIKJ;6%L=05/+6Y,*^:%_NA\9QSTS
M0!;H`*`"@`H`*`"@`H`Y?P]?V?\`PEGBS3OM</V[[>DWV?S!YGE_9+8;]O7;
MGC/3-`'44`%`!0`4`%`!0`4`%`!0`4`>.7=G;67BWQ%;VL$<,45VBHJ*`%!M
MXG(^FYF/XUU82C""<HJS9X7$688K%5(4JTVXQ6B^;U\WYL=7:?,!0!N_#W_D
M:=?_`.O.S_\`0[BN'$_&?59+_N[]?T1Z)7,>T%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0!\\7/\`R%]8_P"PI>?^E$E8RW/G\9_'E\OR&5)RA0!;\,_>U?\`
MZ_!_Z)BKU,)_#.3&[P]/U9O5UG`%`&[\/?\`D:=?_P"O.S_]#N*X<3\9]5DO
M^[OU_1'HE<Q[04`%`!0`4`%`!0`4`0W=I;W]I+:W42RP2KM=&&012E%25F:4
MJLZ,U4INS1S%I=W'A*[BTS4Y6FTF5MEG>.<F(]HY#_)JYHR=%\LMNC_1GL5:
M4,Q@Z]!6J+XH]_[T?U1UM=1X84`%`!0`4`?,^B?\@#3O^O:/_P!!%8/<^:K_
M`,67JR]2,@H`](^$?_((UW_L*'_TG@K:.Q[^#_@1^?YGH54=84`%`!0`4`%`
M!0`4`%`!0!S_`(>_Y#GBS_L*)_Z1VU`'04`%`!0`4`%`!0`4`>8-\+Y@D<L:
M6"W:R1RF8EMV];SSMV=N<^664'MG'`H`]/H`*`"@`H`*`"@`H`Y_P]_R'/%G
M_843_P!([:@#H*`"@`H`*`"@`H`*`/'[SXC^*EU348;?^R4@M[R>WC$EI(S;
M8Y60$D2@$X7/05#E9V//K8WV4W#EV\R+_A8_C#_GIHW_`(`R_P#QZESF7]H_
MW?Q_X`?\+'\8?\]-&_\``&7_`./4<X?VC_=_'_@&=I&I7FKZAK=]?F$W4MXN
M_P`B,HG$$0&`68C@#N:]'"N\+GB9I4]K4C.UM/U9JUU'EA0!N_#W_D:=?_Z\
M[/\`]#N*X<3\9]5DO^[OU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`'SQ<_\A?6/^PI>?^E$E8RW/G\9_'E\OR&5)RA0!;\,_>U?_K\'_HF*O4PG
M\,Y,;O#T_5F]76<`4`;OP]_Y&G7_`/KSL_\`T.XKAQ/QGU62_P"[OU_1'HE<
MQ[04`%`!0`4`%`!0`4`%`$-W:6]_:2VMU$LL$J[71AD$4I14E9FE*K.C-5*;
MLT<Y;7,_A2ZCT_4)6ETB5@EK=N<F$]HY#Z>C?@:YTW1?++;H_P!&>M4IPS&#
MK45:HOBCW_O1_5?-'4UTGBA0`4`%`'S/HG_(`T[_`*]H_P#T$5@]SYJO_%EZ
MLO4C(*`/2/A'_P`@C7?^PH?_`$G@K:.Q[^#_`($?G^9Z%5'6%`!0`4`%`!0`
M4`%`!0`4`<_X>_Y#GBS_`+"B?^D=M0!T%`!0`4`<]JNM:Q9>(;#3K72[*>"\
MW;)I;YXV7:,ME1$W;ISS[4`=#0`4`%`'(GQK,OBNYT@Z9']E@O8[$W`NOWA>
M2$2*?+V_=Y(/S=LX/.`#KJ`"@`H`*`"@`H`*`.7\/7$O_"6>++;[%-Y/V])/
MM64\O=]DMALQNW[N_P!W&.^>*`.HH`*`"@`H`*`"@`H`^>+G_D+ZQ_V%+S_T
MHDK&6Y\_C/X\OE^0RI.4*`+?AG[VK_\`7X/_`$3%7J83^&<F-WAZ?JS>KK.`
M*`-WX>_\C3K_`/UYV?\`Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`/GBY_Y"^L?]A2\_P#2B2L9;GS^,_CR^7Y#*DY0H`M^
M&?O:O_U^#_T3%7J83^&<F-WAZ?JS>KK.`*`-WX>_\C3K_P#UYV?_`*'<5PXG
MXSZK)?\`=WZ_HCT2N8]H*`"@`H`*`"@`H`*`"@`H`BN;:"\MI+:YB66&12KH
MPR"*32DK,NG4G2FIP=FCF8;R;PC<1V.HR/+HTC!+:\<Y,!/2.0^GHWX&N=2=
M%\LOAZ/MZGL2I1S*+JT5:JOBCW\X^?=?<=6#D9'2ND\0*`"@#YGT3_D`:=_U
M[1_^@BL'N?-5_P"++U9>I&04`>D?"/\`Y!&N_P#84/\`Z3P5M'8]_!_P(_/\
MST*J.L*`"@`H`*`"@`H`*`"@`H`Y_P`/?\ASQ9_V%$_]([:@#H*`"@`H`IW.
MF0W6I6-^[.);/?Y8!&T[Q@YXH`N4`%`!0!C6GA?2K37K[6Q;K+J%W()#-*BL
MT6(U3"'&5!"#(SUH`V:`"@`H`*`"@`H`*`.?\/?\ASQ9_P!A1/\`TCMJ`.@H
M`*`"@`H`*`"@`H`^>+G_`)"^L?\`84O/_2B2L9;GS^,_CR^7Y#*DY0H`M^&?
MO:O_`-?@_P#1,5>IA/X9R8W>'I^K-ZNLX`H`W?A[_P`C3K__`%YV?_H=Q7#B
M?C/JLE_W=^OZ(]$KF/:"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^>+G_D+Z
MQ_V%+S_THDK&6Y\_C/X\OE^0RI.4*`+?AG[VK_\`7X/_`$3%7J83^&<F-WAZ
M?JS>KK.`*`-WX>_\C3K_`/UYV?\`Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@
M`H`*`"@`H`*`"@`H`BN;:"\MI+:YB66&12KHPR"*32DK,NG4G2FIP=FCE;:Y
MG\&W4=A?RM+H<K;;6Z<Y-L3TCD/]WT;\#7,FZ#Y9?#T?8]NI3AF<'5I*U5?%
M'^;S7GW1UX.1D=*ZCP0H`^9]$_Y`&G?]>T?_`*"*P>Y\U7_BR]67J1D%`'I'
MPC_Y!&N_]A0_^D\%;1V/?P?\"/S_`#/0JHZPH`*`"@`H`*`"@`H`*`(YS,MO
M*UO&DDX4F-)'**S8X!8`D#/?!QZ&@#D_"$VL2>(/%(O[&R@C-^I=H+QY2)/L
MMOA0#&N5VX.[(.>,=Z`./;PG?ZMJ^LP7$$MN76Z>\N)+)I([D_:5>W&.!-B(
M,``WR]..E`'3^")-?AU?4;35M.:*.15N//9&RQ*IM4OG:V!E,#D&(D_?%`'<
MT`>;^(["\7XH:9J5K87-X<P1%9+9_+C3<VZ2.=#A,!B61^'PH`/&`#TB@`H`
M*`.'B\%WR_$R;Q++>%[8G=%MF570>7L\HKY1+)G+8$@&3G;D9(!W%`!0`4`%
M`!0`4`%`'+^'DO/^$L\6/Y\/V'[>@\GR3YGF?9+;YM^[&W'&W;G/.>U`'44`
M%`!0`4`%`!0`4`?/%S_R%]8_["EY_P"E$E8RW/G\9_'E\OR&5)RA0!;\,_>U
M?_K\'_HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y&G7_P#KSL__`$.XKAQ/QGU6
M2_[N_7]$>B5S'M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?/%S_`,A?6/\`
ML*7G_I1)6,MSY_&?QY?+\AE2<H4`6_#/WM7_`.OP?^B8J]3"?PSDQN\/3]6;
MU=9P!0!N_#W_`)&G7_\`KSL__0[BN'$_&?59+_N[]?T1Z)7,>T%`!0`4`%`!
M0`4`%`!0`4`%`!0!%<6\-W;R6]Q$DL,@VNCC(8>XI-)JS+IU)4Y*<'9HYF">
M;P?<1V=Y(TNA2,%M[ESDVI/2-S_=]&[=#VKG3=%V?P_D>Q.$<SBZE-6JK=?S
M>:\^Z^:.K!R,CI72>(?,^B?\@#3O^O:/_P!!%8/<^:K_`,67JR]2,@H`](^$
M?_((UW_L*'_TG@K:.Q[^#_@1^?YGH54=84`%`!0`4`%`!0`4`%`!0!S_`(>_
MY#GBS_L*)_Z1VU`'04`%`!0!Q>L>/#I7B6;25M;&0PF$;'O]ES+YG>.'8=^.
M_P`PZ&@#M*`"@`H`Y&3QI-%XO;1CI:FU6_2P^T_:/F\Q[?SP=FWIC(/S>GKP
M`==0`4`%`!0`4`%`!0!S_A[_`)#GBS_L*)_Z1VU`'04`%`!0`4`%`!0`4`?/
M%S_R%]8_["EY_P"E$E8RW/G\9_'E\OR&5)RA0!;\,_>U?_K\'_HF*O4PG\,Y
M,;O#T_5F]76<`4`;OP]_Y&G7_P#KSL__`$.XKAQ/QGU62_[N_7]$>B5S'M!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?/%S_`,A?6/\`L*7G_I1)6,MSY_&?
MQY?+\AE2<H4`6_#/WM7_`.OP?^B8J]3"?PSDQN\/3]6;U=9P!0!N_#W_`)&G
M7_\`KSL__0[BN'$_&?59+_N[]?T1Z)7,>T%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`1SP0W5O);SQK+#(I5T89#`]B*32:LRX3E3DIP=FCE%NI_!5Q%:WK--X?D;
M9#=,<M:$]$<]T[!NW0^M<UW0=G\/?L>VZ4,TBZE+2LMX])>:\^ZZ[H\6T4%=
M"T]2""+:,$'M\HJWJS\]Q"<:TT][O\R]2,0H`](^$?\`R"-=_P"PH?\`TG@K
M:.Q[^#_@1^?YGH54=84`%`!0`4`%`!0`4`%`!0!S_A[_`)#GBS_L*)_Z1VU`
M'04`%`!0!@ZCX2L-3FNIY9;B.>>6&998G`:%XONLAQQW!SG()%`&]0`4`%`%
M4Z98-<&X:QMS.91-YAB7=Y@78'SC.X+\N>N..E`%J@`H`*`"@`H`*`"@#E_#
MUG%_PEGBR^WS>=]O2+;Y[^7M^R6QSY>=F[_:QG'&<4`=10`4`%`!0`4`%`!0
M!\\7/_(7UC_L*7G_`*425C+<^?QG\>7R_(94G*%`%OPS][5_^OP?^B8J]3"?
MPSDQN\/3]6;U=9P!0!N_#W_D:=?_`.O.S_\`0[BN'$_&?59+_N[]?T1Z)7,>
MT%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!\\7/\`R%]8_P"PI>?^E$E8RW/G
M\9_'E\OR&5)RA0!;\,_>U?\`Z_!_Z)BKU,)_#.3&[P]/U9O5UG`%`&[\/?\`
MD:=?_P"O.S_]#N*X<3\9]5DO^[OU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`1SP0W5O);SQK+#(I5T89#`]B*32:LRX3E3DIP=FCYGTJ>3^RK*68[
MDEA1BW]PE0<'V]#VKSM:$N5_#^1T8FE1SY2J4$HXF-[QZ32ZK^]W74TJZCXM
MIQ=F%`CTCX1_\@C7?^PH?_2>"MH['OX/^!'Y_F>A51UA0`4`%`!0`4`%`!0`
M4`%`'/\`A[_D.>+/^PHG_I';4`=!0`4`%`!0`4`%`!0!QZ>%KV'XCMXAMUM8
M[:5-L[2,)97^3:`@,8:,9`/$A4X/RY.:`.EU6>[M=(O+BPM1=7D4+O#`6V^8
MX!*KGMD\4`<1H/C?4[W2]"9U@NYKJ^^R7TGDM;FV;:6\ORV)8MC'/`QS0!=U
M_P`9WFD>(Y[6.WA>QLTMS.&!\QVF,@7:<X`7R^<@YW=L<@&'<_$37K2TN4>W
ML&O+:V>_++')Y;PK!'*8\;LA\R;=V2.,[>P`-WQ#XQO-+U.VCM8(6ME2UEN5
ME5BS+//Y2A&!`!7ECD'/`XSF@#`M?B1K=W]EMT@L1<WT45Y`[1/LCA>&:78P
MWY9P(-NX$#YLXXP0#T6SU-+C0;?57C=8Y+9;@HB&1@"N[`502Q]@"3VH`YWP
MAK-KJ'B#Q3'#%>HSWZR@SV,T("BUMUP2Z@!LC[IYQSC'-`'84`%`!0`4`%`!
M0`4`?/%S_P`A?6/^PI>?^E$E8RW/G\9_'E\OR&5)RA0!;\,_>U?_`*_!_P"B
M8J]3"?PSDQN\/3]6;U=9P!0!N_#W_D:=?_Z\[/\`]#N*X<3\9]5DO^[OU_1'
MHE<Q[04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'SQ<_\A?6/^PI>?^E$E8RW
M/G\9_'E\OR&5)RA0!;\,_>U?_K\'_HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y
M&G7_`/KSL_\`T.XKAQ/QGU62_P"[OU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`'S-HG_(`TX?\`3M'_`.@BN>23NF?.SJ3I5W.#LT]'\RR/]'X)
M_<]C_<]C[?RKE3=!V?P_D?2SA3S^FZE-)8E+5=*B[K^]W74FKJ/DVG%V9TO@
M+Q?'H%MK-JVCZA>%[_S/,MC#M&8(1@[Y%.>/3'-=5*G*4;I'J4<90P]*,:DK
M/T?=G6_\++A_Z%G6?SM?_CU:>PJ=C3^U,)_/^#_R#_A9</\`T+.L_G:__'J/
M85.P?VIA/Y_P?^1K^&_%UOXDNKVUCTZ]LIK1(Y'6Z\OYE<N%(*.W>-NN.U9R
MBX.S.NC7IUX\U-W1T-2;!0`4`%`!0`4`%`'/^'O^0YXL_P"PHG_I';4`=!0`
M4`%`!0`4`%`!0!R]QXQ2W\;VGA[[/%*ERS1>?%*[-%(L1DVNNS:,J./G)Y!Q
MCF@#HKNTM[ZSFL[J%9K>=#')&XR&4C!!_"@#(TOP?HFCV%O9VMJWEV]P+E6>
M5F<R`;0S,3EL+QSV`'84`.3PGI/VFVN[B*6[N[=-@GGE9F<`L1O&<,1N;&1Q
MDXQF@"O_`,(%X:^Q&T.FYA+[V!GDRWRA=I;=DIM`783MP`,8H`G/A+2I);::
MZ2:[FMI6ECDGG<G)?>`0"`RJV-H((7`QTH`@_P"$$\-_9Y(/[/.QY!)G[1)N
M4@$`*V[*KAF&U2%PQ&,$T`=#'&D,211J$1`%51T`'04`8/A[_D.>+/\`L*)_
MZ1VU`'04`%`!0`4`%`!0`4`?/%S_`,A?6/\`L*7G_I1)6,MSY_&?QY?+\AE2
M<H4`6_#/WM7_`.OP?^B8J]3"?PSDQN\/3]6;U=9P!0!N_#W_`)&G7_\`KSL_
M_0[BN'$_&?59+_N[]?T1Z)7,>T%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!\
M\7/_`"%]8_["EY_Z425C+<^?QG\>7R_(94G*%`%OPS][5_\`K\'_`*)BKU,)
M_#.3&[P]/U9O5UG`%`&[\/?^1IU__KSL_P#T.XKAQ/QGU62_[N_7]$>B5S'M
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?,^B?\`(`T[_KVC_P#016#W/FJ_
M\67JR][5+2:LR:=2=*:G!V:V9#G[-@'_`%'8_P!SV^G\JYKN@[/X?R/K'"EQ
M!3<Z:4<4MULJB[KM+OW_`"TO#((;5L@C-X,?]^8J]W!M.GH?$9C3G3E!333M
MU_Q,W:[#S0H`W?A[_P`C3K__`%YV?_H=Q7#B?C/JLE_W=^OZ(]$KF/:"@`H`
M*`"@`H`CGGAM;>6XN)4A@B4O))(P544#)))X``[T`<GX0UW1]3\0>*8K#5;*
M[DDOUF18+A'+1BUMU+@`\KN!7/3(Q0!?\6^([GPS8"^CTP7=J@+3NUP(BHR`
M%08)>1B<*O`..2.,@&!>?$X6EM=W`TH&)&D^SL]SM\U8YC$Y;Y3L.Y<*.=VY
M>1G@`Z?0?$=IK[W@MWB!MY=HC$N9"O3>R8!4%@X'4$*"#SP`;-`!0`4`%`&6
M;#1&U_SC8V9U=4$OG>0OG!>4!W8ST+`<^M`&I0`4`%`!0`4`%`!0!R_AY[S_
M`(2SQ8GD0_8?MZ'S?./F>9]DMOEV;<;<<[MV<\8[T`=10`4`%`!0`4`%`!0!
M\\7/_(7UC_L*7G_I1)6,MSY_&?QY?+\AE2<H4`6_#/WM7_Z_!_Z)BKU,)_#.
M3&[P]/U9O5UG`%`&[\/?^1IU_P#Z\[/_`-#N*X<3\9]5DO\`N[]?T1Z)7,>T
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!\\7/_(7UC_L*7G_`*425C+<^?QG
M\>7R_(94G*%`%OPS][5_^OP?^B8J]3"?PSDQN\/3]6;U=9P!0!N_#W_D:=?_
M`.O.S_\`0[BN'$_&?59+_N[]?T1Z)7,>T%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0!\SZ)_R`-._Z]H__016#W/FJ_\`%EZLO4C(..A&14R7,FC;#UI8>K&K
M'>+3^XG\*0>4=0`D9A'*(B,8&=BMG\G'Y5TY9AI4N:;>Y[_%_$%#-Z=&%.FT
MU=W=KZZ67EI?[CHJ]@^`"@#=^'O_`"-.O_\`7G9_^AW%<.)^,^JR7_=WZ_HC
MT2N8]H*`"@`H`*`"@`H`Y_P]_P`ASQ9_V%$_]([:@"#5?`VG:A>6UU:SS:5)
M!.UR18Q0!99F_P"6CAXV#,.Q//)H`FL/!]CIDM[+:W5VC7*2(GS+_HPD<N_E
M_+QEV+?-GGV&*`)=%\*:=H%[-<6'F(DD:1K!E?+B"@#Y<#/(5<Y)Z<8YH`W*
M`"@`H`*`,+^PROCC^W5MK1E>Q%LTIXF0ARW'R\@@\\C[HX/8`W:`"@`H`*`"
M@`H`*`.?\/?\ASQ9_P!A1/\`TCMJ`.@H`*`"@`H`*`"@`H`^>+G_`)"^L?\`
M84O/_2B2L9;GS^,_CR^7Y#*DY0H`M^&?O:O_`-?@_P#1,5>IA/X9R8W>'I^K
M-ZNLX`H`W?A[_P`C3K__`%YV?_H=Q7#B?C/JLE_W=^OZ(]$KF/:"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`^>+G_D+ZQ_V%+S_THDK&6Y\_C/X\OE^0RI.4
M*`+?AG[VK_\`7X/_`$3%7J83^&<F-WAZ?JS>KK.`*`-WX>_\C3K_`/UYV?\`
MZ'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/F
M?1/^0!IW_7M'_P"@BL'N?-5_XLO5EZD9!0!;\,_>U?\`Z_!_Z)BKU,)_#.3&
M[P]/U9O5UG`%`&[\/?\`D:=?_P"O.S_]#N*X<3\9]5DO^[OU_1'HE<Q[04`%
M`!0`4`%`!0!S_A[_`)#GBS_L*)_Z1VU`'04`%`!0`4`%`!0`4`9W]H_\5'_9
MF?\`EU\_'E_[>W[V[]-OX]J`-&@`H`*`"@`H`*`"@#E_#UO+_P`)9XLN?MLW
MD_;TC^RX3R]WV2V._.W?N[?>QCMGF@#J*`"@`H`*`"@`H`*`/GBY_P"0OK'_
M`&%+S_THDK&6Y\_C/X\OE^0RI.4*`+?AG[VK_P#7X/\`T3%7J83^&<F-WAZ?
MJS>KK.`*`-WX>_\`(TZ__P!>=G_Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`/GBY_Y"^L?]A2\_]*)*QEN?/XS^/+Y?D,J3
ME"@"WX9^]J__`%^#_P!$Q5ZF$_AG)C=X>GZLWJZS@"@#=^'O_(TZ_P#]>=G_
M`.AW%<.)^,^JR7_=WZ_HCT2N8]H*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#
MYGT3_D`:=_U[1_\`H(K![GS5?^++U9>I&04`6_#/WM7_`.OP?^B8J]3"?PSD
MQN\/3]6;U=9P!0!N_#W_`)&G7_\`KSL__0[BN'$_&?59+_N[]?T1Z)7,>T%`
M!0`4`%`!0`4`<_X>_P"0YXL_["B?^D=M0!T%`!0`4`%`!0`4`%`%?[#;?VC_
M`&AY?^E>5Y._<?N9SC'3K0!8H`*`"@`H`*`"@`H`Y_P]_P`ASQ9_V%$_]([:
M@#H*`"@`H`*`"@`H`*`/GBY_Y"^L?]A2\_\`2B2L9;GS^,_CR^7Y#*DY0H`M
M^&?O:O\`]?@_]$Q5ZF$_AG)C=X>GZLWJZS@"@#=^'O\`R-.O_P#7G9_^AW%<
M.)^,^JR7_=WZ_HCT2N8]H*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#YXN?\`
MD+ZQ_P!A2\_]*)*QEN?/XS^/+Y?D,J3E"@"WX9^]J_\`U^#_`-$Q5ZF$_AG)
MC=X>GZLWJZS@"@#=^'O_`"-.O_\`7G9_^AW%<.)^,^JR7_=WZ_HCT2N8]H*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#YGT3_`)`&G?\`7M'_`.@BL'N?-5_X
MLO5EZD9!0!;\,_>U?_K\'_HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y&G7_P#K
MSL__`$.XKAQ/QGU62_[N_7]$>B5S'M!0`4`%`!0`4`%`'/\`A[_D.>+/^PHG
M_I';4`=!0`4`%`!0`4`%`!0!Q4NG>)#X[:Y!NS9&XC:.9;L"V2V$6'B:'=S(
M9,G=M/!'S#&*`.UH`*`"@`H`*`"@`H`Y?P]86?\`PEGBS4/LD/V[[>D/VCRQ
MYGE_9+8[-W7;GG'3-`'44`%`!0`4`%`!0`4`?/%S_P`A?6/^PI>?^E$E8RW/
MG\9_'E\OR&5)RA0!;\,_>U?_`*_!_P"B8J]3"?PSDQN\/3]6;U=9P!0!N_#W
M_D:=?_Z\[/\`]#N*X<3\9]5DO^[OU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`'SQ<_\A?6/^PI>?^E$E8RW/G\9_'E\OR&5)RA0!;\,_>U?_K\'
M_HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y&G7_`/KSL_\`T.XKAQ/QGU62_P"[
MOU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'S/HG_(`T[_KVC_\`
M016#W/FJ_P#%EZLO4C(*`+?AG[VK_P#7X/\`T3%7J83^&<F-WAZ?JS>KK.`*
M`-WX>_\`(TZ__P!>=G_Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@`H`*`"@#G
M_#W_`"'/%G_843_TCMJ`-NXN8+2$S7,\<,0(!>1@H!)P!D^I(%`%277M'A^T
M^;JUE']E=8Y]UP@\IF^ZK<_*3D8!H`MQ7,$[S)#-'(\+;)%1@2C8#8/H<,#@
M]B/6@"6@`H`*`"@#FW\:6,?B9M#:SO!(MTMH;C:GE>:T/G*OWMW*9YVXR#[9
M`.DH`*`"@`H`*`"@`H`Y?P]>1?\`"6>++'9-YWV])=WD/Y>W[);#'F8V;O\`
M9SG'.,4`=10`4`%`!0`4`%`!0!\\7/\`R%]8_P"PI>?^E$E8RW/G\9_'E\OR
M&5)RA0!;\,_>U?\`Z_!_Z)BKU,)_#.3&[P]/U9O5UG`%`&[\/?\`D:=?_P"O
M.S_]#N*X<3\9]5DO^[OU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`'SQ<_\`(7UC_L*7G_I1)6,MSY_&?QY?+\AE2<H4`6_#/WM7_P"OP?\`HF*O
M4PG\,Y,;O#T_5F]76<`4`;OP]_Y&G7_^O.S_`/0[BN'$_&?59+_N[]?T1Z)7
M,>T%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!\SZ)_P`@#3O^O:/_`-!%8/<^
M:K_Q9>K+U(R"@"WX9^]J_P#U^#_T3%7J83^&<F-WAZ?JS>KK.`*`-WX>_P#(
MTZ__`->=G_Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@`H`*`(YUF:WE6WD2.<
MJ1&\B%U5L<$J""1GMD?44`<GX0AUB/Q!XI-_?64\8OU#K!9O$3)]EM\,"9&P
MNW`VX)SSGM0!1\<:#XLUFVBAMO[.O[:*Y$ZPAWM'!61#'DY</M`?/W0200.,
M$`S+?P+J%Q%?V^HVLT:0I=;'MYH]UVTEP\HVELX&URAW@'+''8T`=!X,TOQ!
MH]Y>VNJ2&2T*K(D@V;&D;ERO)?J6&&.``@7@&@#L:`"@`H`*`,I_#FDR:B;]
MK3-T;I;POYC?ZU8O*#8SC[G&.G?&>:`-6@`H`*`"@`H`*`"@#G_#W_(<\6?]
MA1/_`$CMJ`.@H`*`"@`H`*`"@`H`^>+G_D+ZQ_V%+S_THDK&6Y\_C/X\OE^0
MRI.4*`+?AG[VK_\`7X/_`$3%7J83^&<F-WAZ?JS>KK.`*`-WX>_\C3K_`/UY
MV?\`Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`/GBY_Y"^L?]A2\_P#2B2L9;GS^,_CR^7Y#*DY0H`M^&?O:O_U^#_T3%7J8
M3^&<F-WAZ?JS>KK.`*`-WX>_\C3K_P#UYV?_`*'<5PXGXSZK)?\`=WZ_HCT2
MN8]H*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#YGT3_D`:=_U[1_^@BL'N?-5
M_P"++U9>I&04`6_#/WM7_P"OP?\`HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y&
MG7_^O.S_`/0[BN'$_&?59+_N[]?T1Z)7,>T%`!0`4`%`!0`4`<_X>_Y#GBS_
M`+"B?^D=M0!T%`!0`4`%`!0`4`%`!0`4`<O\19)HO`6JO!J+:>X1?WX5S@;A
MD$H"R@C(+#[N<]J`.#A\074T.@WFGW5PMSY"11:/)-<.TH\QT-PDOF!9EX#?
M,K84#IN%`&?=:]J*:/=-;:W?O9K"[V]P;E][7PMHV6$-U;,A?]WR-PVXXV@`
MZCQ/KMXVN:;]BU%@_P#HRVT=O.=L\WVG9<HR@X?:@Y!SMY/&,@`Y6UU_5'MX
M1<ZS>I8N(6U"<73YAO#!<,\6[.8_WJPCRQ@9(&/FP0#V73Y;]_#EK-)$KZBU
MJK-'*Q13+L!P2`=HSU.#CT-`&!X0FUB3Q!XI%_8V4$9OU+M!>/*1)]EM\*`8
MURNW!W9!SQCO0!V%`!0`4`%`!0`4`%`'SQ<_\A?6/^PI>?\`I1)6,MSY_&?Q
MY?+\AE2<H4`6_#/WM7_Z_!_Z)BKU,)_#.3&[P]/U9O5UG`%`&[\/?^1IU_\`
MZ\[/_P!#N*X<3\9]5DO^[OU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`'SQ<_P#(7UC_`+"EY_Z425C+<^?QG\>7R_(94G*%`%OPS][5_P#K\'_H
MF*O4PG\,Y,;O#T_5F]76<`4`;OP]_P"1IU__`*\[/_T.XKAQ/QGU62_[N_7]
M$>B5S'M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?,^B?\@#3O\`KVC_`/01
M6#W/FJ_\67JR]2,@H`M^&?O:O_U^#_T3%7J83^&<F-WAZ?JS>KK.`*`-WX>_
M\C3K_P#UYV?_`*'<5PXGXSZK)?\`=WZ_HCT2N8]H*`"@`H`*`"@`H`Y_P]_R
M'/%G_843_P!([:@#H*`"@`H`*`"@`H`*`"@`H`1E5U*LH92,$$9!%``JA%"J
M`%`P`.@H`6@".&"*WC\N")(DR6VHH`R3DG`]22:`)*`"@#G_``]_R'/%G_84
M3_TCMJ`.@H`*`"@`H`*`"@`H`^>+G_D+ZQ_V%+S_`-*)*QEN?/XS^/+Y?D,J
M3E"@"WX9^]J__7X/_1,5>IA/X9R8W>'I^K-ZNLX`H`W?A[_R-.O_`/7G9_\`
MH=Q7#B?C/JLE_P!W?K^B/1*YCV@H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/
MGBY_Y"^L?]A2\_\`2B2L9;GS^,_CR^7Y#*DY0H`M^&?O:O\`]?@_]$Q5ZF$_
MAG)C=X>GZLWJZS@"@#=^'O\`R-.O_P#7G9_^AW%<.)^,^JR7_=WZ_HCT2N8]
MH*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#YGT3_D`:=_U[1_^@BL'N?-5_XL
MO5EZD9!0!;\,_>U?_K\'_HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y&G7_`/KS
ML_\`T.XKAQ/QGU62_P"[OU_1'HE<Q[04`%`!0`4`%`!0!S_A[_D.>+/^PHG_
M`*1VU`'04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!R_AZWE_X2SQ9<_;9O
M)^WI']EPGE[OLEL=^=N_=V^]C';/-`'44`%`!0`4`%`!0`4`?/%S_P`A?6/^
MPI>?^E$E8RW/G\9_'E\OR&5)RA0!;\,_>U?_`*_!_P"B8J]3"?PSDQN\/3]6
M;U=9P!0!N_#W_D:=?_Z\[/\`]#N*X<3\9]5DO^[OU_1'HE<Q[04`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`'SQ<_\A?6/^PI>?^E$E8RW/G\9_'E\OR&5)RA0
M!;\,_>U?_K\'_HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y&G7_`/KSL_\`T.XK
MAQ/QGU62_P"[OU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'S/HG
M_(`T[_KVC_\`016#W/FJ_P#%EZLO4C(*`+?AG[VK_P#7X/\`T3%7J83^&<F-
MWAZ?JS>KK.`*`-WX>_\`(TZ__P!>=G_Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*
M`"@`H`*`"@#G_#W_`"'/%G_843_TCMJ`.@H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@#G_#W_(<\6?]A1/_`$CMJ`.@H`*`"@`H`*`"@`H`^>+G_D+ZQ_V%
M+S_THDK&6Y\_C/X\OE^0RI.4*`+?AG[VK_\`7X/_`$3%7J83^&<F-WAZ?JS>
MKK.`*`-WX>_\C3K_`/UYV?\`Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`/GBY_Y"^L?]A2\_P#2B2L9;GS^,_CR^7Y#*DY0
MH`M^&?O:O_U^#_T3%7J83^&<F-WAZ?JS>KK.`*`-WX>_\C3K_P#UYV?_`*'<
M5PXGXSZK)?\`=WZ_HCT2N8]H*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#YGT
M3_D`:=_U[1_^@BL'N?-5_P"++U9>I&04`6_#/WM7_P"OP?\`HF*O4PG\,Y,;
MO#T_5F]76<`4`;OP]_Y&G7_^O.S_`/0[BN'$_&?59+_N[]?T1Z)7,>T%`!0`
M4`%`!0!'//#:V\MQ<2I#!$I>221@JHH&223P`!WH`Y/PAKNCZGX@\4Q6&JV5
MW))?K,BP7".6C%K;J7`!Y7<"N>F1B@"MXI\?0Z9=06FDWVGR2`3M<2R!YXX3
M$4#(_E9,9_>#+$$*`20:`,Z7Q[X@E@NI+'3H)V<S-:QI;R2,J17#0D.%;+%B
MH.1@+NYR%R0#I?"GBR#Q*;S9(@9'W11K&P_=8`5M_*OGEOEZ*RY`/4`Z6@`H
M`*`"@`H`*`"@`H`*`"@`H`*`.7\/6%G_`,)9XLU#[)#]N^WI#]H\L>9Y?V2V
M.S=UVYYQTS0!U%`!0`4`%`!0`4`%`'SQ<_\`(7UC_L*7G_I1)6,MSY_&?QY?
M+\AE2<H4`6_#/WM7_P"OP?\`HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y&G7_^
MO.S_`/0[BN'$_&?59+_N[]?T1Z)7,>T%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0!\\7/_(7UC_L*7G_I1)6,MSY_&?QY?+\AE2<H4`6_#/WM7_Z_!_Z)BKU,
M)_#.3&[P]/U9O5UG`%`&[\/?^1IU_P#Z\[/_`-#N*X<3\9]5DO\`N[]?T1Z)
M7,>T%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!\SZ)_R`-._Z]H__`$$5@]SY
MJO\`Q9>K+U(R"@"WX9^]J_\`U^#_`-$Q5ZF$_AG)C=X>GZLWJZS@"@#=^'O_
M`"-.O_\`7G9_^AW%<.)^,^JR7_=WZ_HCT2N8]H*`"@`H`*`"@`H`Y_P]_P`A
MSQ9_V%$_]([:@"YK/A[2_$$4<>IVQF6/(&V5X\@C#*=I&Y3@94Y!P,CB@!EO
MX8T>U>^>WM#$U\&6;;*XX8DL%Y^3)))VXY)/7F@":QT+3=-OI[RSMA%-.JH^
M';;A1@87.%X`S@#.!G.!0!HT`%`!0`4`%`!0`4`%`!0`4`%`!0!R_AZ\B_X2
MSQ98[)O.^WI+N\A_+V_9+88\S&S=_LYSCG&*`.HH`*`"@`H`*`"@`H`^>+G_
M`)"^L?\`84O/_2B2L9;GS^,_CR^7Y#*DY0H`M^&?O:O_`-?@_P#1,5>IA/X9
MR8W>'I^K-ZNLX`H`W?A[_P`C3K__`%YV?_H=Q7#B?C/JLE_W=^OZ(]$KF/:"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^>+G_D+ZQ_V%+S_THDK&6Y\_C/X\
MOE^0RI.4*`+?AG[VK_\`7X/_`$3%7J83^&<F-WAZ?JS>KK.`*`-WX>_\C3K_
M`/UYV?\`Z'<5PXGXSZK)?]W?K^B/1*YCV@H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`/F?1/^0!IW_7M'_P"@BL'N?-5_XLO5EZD9!0!;\,_>U?\`Z_!_Z)BK
MU,)_#.3&[P]/U9O5UG`%`&[\/?\`D:=?_P"O.S_]#N*X<3\9]5DO^[OU_1'H
ME<Q[04`%`!0`4`%`!0!S_A[_`)#GBS_L*)_Z1VU`'04`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0!S_A[_D.>+/^PHG_`*1VU`'04`%`!0`4`%`!0`4`?/%S
M_P`A?6/^PI>?^E$E8RW/G\9_'E\OR&5)RA0!;\,_>U?_`*_!_P"B8J]3"?PS
MDQN\/3]6;U=9P!0!N_#W_D:=?_Z\[/\`]#N*X<3\9]5DO^[OU_1'HE<Q[04`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'SQ<_\A?6/^PI>?^E$E8RW/G\9_'E\
MOR&5)RA0!;\,_>U?_K\'_HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_Y&G7_`/KS
ML_\`T.XKAQ/QGU62_P"[OU_1'HE<Q[04`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`'S/HG_(`T[_KVC_\`016#W/FJ_P#%EZLO4C(*`+?AG[VK_P#7X/\`T3%7
MJ83^&<F-WAZ?JS>KK.`*`-WX>_\`(TZ__P!>=G_Z'<5PXGXSZK)?]W?K^B/1
M*YCV@H`*`"@`H`*`"@#G_#W_`"'/%G_843_TCMJ`.@H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@#E_#SWG_``EGBQ/(A^P_;T/F^<?,\S[);?+LVXVXYW;L
MYXQWH`ZB@`H`*`"@`H`*`"@#YXN?^0OK'_84O/\`THDK&6Y\_C/X\OE^0RI.
M4*`+?AG[VK_]?@_]$Q5ZF$_AG)C=X>GZLWJZS@"@#=^'O_(TZ_\`]>=G_P"A
MW%<.)^,^JR7_`'=^OZ(]$KF/:"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^>
M+G_D+ZQ_V%+S_P!*)*QEN?/XS^/+Y?D,J3E"@"WX9^]J_P#U^#_T3%7J83^&
M<F-WAZ?JS>KK.`*`-WX>_P#(TZ__`->=G_Z'<5PXGXSZK)?]W?K^B/1*YCV@
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/F?1/^0!IW_7M'_Z"*P>Y\U7_BR]
M67J1D%`%OPS][5_^OP?^B8J]3"?PSDQN\/3]6;U=9P!0!N_#W_D:=?\`^O.S
M_P#0[BN'$_&?59+_`+N_7]$>B5S'M!0`4`%`!0`4`%`'/^'O^0YXL_["B?\`
MI';4`=!0`4`%`!0`4`%`!0`4`%`!0`4`%`%&RUC3=1NKNULKZ">>S<1SQQN"
M8VP#@_G_`#'4&@"]0`4`<_X>_P"0YXL_["B?^D=M0!T%`!0`4`%`!0`4`%`'
MSQ<_\A?6/^PI>?\`I1)6,MSY_&?QY?+\AE2<H4`6_#/WM7_Z_!_Z)BKU,)_#
M.3&[P]/U9O5UG`%`&[\/?^1IU_\`Z\[/_P!#N*X<3\9]5DO^[OU_1'HE<Q[0
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'SQ<_P#(7UC_`+"EY_Z425C+<^?Q
MG\>7R_(94G*%`%OPS][5_P#K\'_HF*O4PG\,Y,;O#T_5F]76<`4`;OP]_P"1
MIU__`*\[/_T.XKAQ/QGU62_[N_7]$>B5S'M!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`?,^B?\@#3O\`KVC_`/016#W/FJ_\67JR]2,@H`M^&?O:O_U^#_T3
M%7J83^&<F-WAZ?JS>KK.`*`-WX>_\C3K_P#UYV?_`*'<5PXGXSZK)?\`=WZ_
MHCT2N8]H*`"@`H`*`"@`H`Y_P]_R'/%G_843_P!([:@#6O=3L--\G[=?6]KY
M[B.+SI53S'/15R>3["@"&77M'A^T^;JUE']E=8Y]UP@\IF^ZK<_*3D8!H`MQ
M7,$[S)#-'(\+;)%1@2C8#8/H<,#@]B/6@"6@`H`*`"@`H`*`"@`H`*`//?"6
MD>)M.UG6X8$CTW2S>B5([J,7`?*C=Y;*R'!XY;.,8P<&@#T*@".>-IK>6))G
M@=U*K+&%+(2/O#<",CKR"/8T`<?I7A36K?4=<DE\4:M"EQ>+)&ZI9DS*+>)=
MY'DG!RK+@`<(#CG)`-3_`(1[5/\`H<]9_P"_5G_\8H`/^$>U3_H<]9_[]6?_
M`,8H`/\`A'M4_P"ASUG_`+]6?_QB@`_X1[5/^ASUG_OU9_\`QB@`_P"$>U3_
M`*'/6?\`OU9__&*`#_A'M4_Z'/6?^_5G_P#&*`#_`(1[5/\`H<]9_P"_5G_\
M8H`YUOA)I[S32MXAUDO-*\SG-OR[L68_ZGN234N*9SSPU*<N:2U#_A4>G?\`
M0PZS^=O_`/&:.5$?4Z'\OXL/^%1Z=_T,.L_G;_\`QFCE0?4Z'\OXL=:_">QL
MO.^S^(M93SG\Q_\`CV.6VA<\P^BC\JUA4E!6B3/`8>I;FCMYO_,L?\*TA_Z&
M;6?RM?\`XS5^WJ=S/^R\)_)^+_S#_A6D/_0S:S^5K_\`&:/;U.X?V7A/Y/Q?
M^9/I_@!M*NKBYLO%6LQ37")'(VVU;<J%BHP8.,%V_.LY2<G=G71H4\/'EIJR
M-'_A'M4_Z'/6?^_5G_\`&*DV#_A'M4_Z'/6?^_5G_P#&*`#_`(1[5/\`H<]9
M_P"_5G_\8H`/^$>U3_H<]9_[]6?_`,8H`/\`A'M4_P"ASUG_`+]6?_QB@`_X
M1[5/^ASUG_OU9_\`QB@`_P"$>U3_`*'/6?\`OU9__&*`,O2O"FM6^HZY)+XH
MU:%+B\62-U2S)F46\2[R/).#E67``X0''.2`:G_"/:I_T.>L_P#?JS_^,4`'
M_"/:I_T.>L_]^K/_`.,4`'_"/:I_T.>L_P#?JS_^,4`'_"/:I_T.>L_]^K/_
M`.,4`'_"/:I_T.>L_P#?JS_^,4`'_"/:I_T.>L_]^K/_`.,4`'_"/:I_T.>L
M_P#?JS_^,4`<ZWPDT]YII6\0ZR7FE>9SFWY=V+,?]3W))J7%,YYX:E.7-):A
M_P`*CT[_`*&'6?SM_P#XS1RHCZG0_E_%A_PJ/3O^AAUG\[?_`.,T<J#ZG0_E
M_%CK7X3V-EYWV?Q%K*><_F/_`,>QRVT+GF'T4?E6L*DH*T29X##U+<T=O-_Y
MEC_A6D/_`$,VL_E:_P#QFK]O4[F?]EX3^3\7_F'_``K2'_H9M9_*U_\`C-'M
MZG</[+PG\GXO_,GT_P``-I5U<7-EXJUF*:X1(Y&VVK;E0L5&#!Q@NWYUG*3D
M[LZZ-"GAX\M-61H_\(]JG_0YZS_WZL__`(Q4FP?\(]JG_0YZS_WZL_\`XQ0`
M?\(]JG_0YZS_`-^K/_XQ0`?\(]JG_0YZS_WZL_\`XQ0`?\(]JG_0YZS_`-^K
M/_XQ0`?\(]JG_0YZS_WZL_\`XQ0`?\(]JG_0YZS_`-^K/_XQ0!EZ5X4UJWU'
M7))?%&K0I<7BR1NJ69,RBWB7>1Y)P<JRX`'"`XYR0#4_X1[5/^ASUG_OU9__
M`!B@`_X1[5/^ASUG_OU9_P#QB@`_X1[5/^ASUG_OU9__`!B@`_X1[5/^ASUG
M_OU9_P#QB@`_X1[5/^ASUG_OU9__`!B@`_X1[5/^ASUG_OU9_P#QB@`_X1[5
M/^ASUG_OU9__`!B@#F8/@YI5M;QP1:_K*QQ*$4;K<X`&!_RQJ>5'-+"49-MK
M\R3_`(5'IW_0PZS^=O\`_&:.5$_4Z'\OXL/^%1Z=_P!##K/YV_\`\9HY4'U.
MA_+^+'6OPGL;+SOL_B+64\Y_,?\`X]CEMH7/,/HH_*M85)05HDSP&'J6YH[>
M;_S+'_"M(?\`H9M9_*U_^,U?MZG<S_LO"?R?B_\`,/\`A6D/_0S:S^5K_P#&
M:/;U.X?V7A/Y/Q?^9/I_@!M*NKBYLO%6LQ37")'(VVU;<J%BHP8.,%V_.LY2
M<G=G71H4\/'EIJR-'_A'M4_Z'/6?^_5G_P#&*DV#_A'M4_Z'/6?^_5G_`/&*
M`#_A'M4_Z'/6?^_5G_\`&*`#_A'M4_Z'/6?^_5G_`/&*`#_A'M4_Z'/6?^_5
MG_\`&*`#_A'M4_Z'/6?^_5G_`/&*`#_A'M4_Z'/6?^_5G_\`&*`*_AC0=2TK
M6M>N;W5;VZAN;I6B6<08E'D0KYA\M%(8%&3'`PN<9.X@'/\`C[PSXEUF6!K>
M."^'EW,*>0BP[$D,>U)?,D.Y#L.YDP_`V@<T`5K?P+J%Q%?V^HVLT:0I=;'M
MYH]UVTEP\HVELX&URAW@'+''8T`=!X,TOQ!H]Y>VNJ2&2T*K(D@V;&D;ERO)
M?J6&&.``@7@&@#L:`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`.!\1>,=8T77Y=/B6PG$@C6-41V:U\R6.*-Y3N`.XNQV#!PG4\X`&1^
M/=3$.B/)I\+1W$]W!=3*<`M`LW$:Y)&3"#SG`..3R`#=\(ZYJ&KI>1ZFEL)X
M#$RM;AE4K)$L@!#$G(W$9SSC.!G``.DH`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`\_P!;\9ZUI&OW6G*NGS@B-8_+1V-H9)HXHC,=P#;M[-M`
M7&S&3UH`M:1XPU2_NM$ADL(?+NI+J"XG0X#20F1<1H22,F//S'@$#GD@`V_#
M&KWFLV%U-?6J6L\-W+!Y2-NVA&P,GN?7'%`&W0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0!Y_K?C/6M(U^ZTY5T^<$1K'Y:.QM#)-'%$9CN`;=
MO9MH"XV8R>M`$^D^,=9U*XTZV&GVH:>.\1IV<HCS0.4PJY8JI(R2<D`X&<9H
M`U?!VMW^MV=\]Z;686UT8([JT1DBN`%7<5#,QP&++G)SM_"@#I*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@#GY/!6A27>H7+6]QYFH'=<@7LP5VXPVT/@,-HPP`(P,8H`MQ^
M&M(B@T^%;3]WI[,]N&D8[6965B23\Q(=LELYSGKS0!)H^@Z;H$$L.FVWDI*P
M=\NSDD`*.6).`H``Z```<4`:-`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`'/#P1H(GU";[/<[M1<R7(^W3[7<D'<%WX5AM&"`"N!C%`%^UT#3+
M-+!(+;:+`L;?,C$J6!#$DG+$Y.2V3DYZT`6;.PMK!9EMH_+$TK3/\Q.78Y8\
M^]`%F@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#GAX(T$3ZA-]
MGN=VHN9+D?;I]KN2#N"[\*PVC!`!7`QB@"S_`,(OHXLH+06K+%;Q2PQ[9I`P
M63[_`,V[))Z[B<YYSF@";1-!L/#M@MCIB31VJXV1RW,DP0`8`7>QVCCH.*`-
M*@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@#BOB7K.J:-I&EMI5\]E+<7XA>1(T<[/)E;&'5AU1>U)NR,*]1TJ;FCS
M[_A+/%O_`$--Y_X#6O\`\:K/G9YG]H5>R_KYGI_P^U.^U?P7:7FI7)N;HS7"
M-*R*I8).Z+D*`.BCH*T6QZ].3E!2?5'3TRSF->\57.@ZW!:RZ?`]@]I-=O<?
M:6$B+$4#@1[""?WBX^89YSC'(!F7?Q*AL;BZ,^B:AY%M;AW1/*:7S-[*8POF
M8)`0M\I(P#SQR`;MKXF@N/#E_K9@<6]GYY*K\S.L>>0,=2!TH`HIXU^SRQVV
MI::8[ACEOLEPDZ1QG9AV)VD<R(-NTGG(R.:`*5I\3]/N[%;Q=&U6.)XQ)'O6
M$%P0K*!B3J0X/..ASCN`-?XJZ.EPMN--U5Y2KY"VZE5D5V0Q%]VT/E&[[3CK
MR,@$X^)6E%WC-C>K(D)D*,85)<,5\D`R?,^5/`R/>@"M9?$N*\>6;^R+M+/"
M>26V"1V:-6V;=W#;F"\D`=<GG`!H:=X_T[4M7M=.CL;Z-YW,7F2*FR.4>;F-
ML.3N'D2<@%>.O(H`KM\3-(2ZEMVL[U7BNOLY9O*5"O/[T,7`,?!YSGCI0!-X
MC^(6F^&+F>*]T[4I8X&56FMX5=<E2YXW;L*@+$XP`*`(O^%E:9YTD(T[4#()
M)4C4+%^^$3.LCK\^`J^6WWL$XX!H`J7/Q1M()Q*NDW[V`%RN]$5I)7BFBA`C
M0-DAGEVC.#G'&,D`&IH_CJTUW5[6SL;&Y\F>$R&XEVJ%.R.39MR6W;95)R`.
M>":`&^'?'=MX@U%;!=.NH)O+WF1BC1%@D;E`=VXD+,G)4#KZ4`9Z_$6Y2\M+
M>ZT+R?/N/*)%VKX4R0Q`KA<.P><*P!P-K?,>,@%M/',AO=/@FTM8!<WDEI*7
MNE+0D.44X`.=S#'4#)`!8D`@$=SX_FLM5OK>;0+J6UMYUMHY;<L6DE9T15^=
M4CY+]I#C!SB@":;XAZ;;AC)87RCS4C7Y8_GWLR(P^?H70IS@@D$@+\U`%MO%
M]O+I&JWEE:22R:>"KQRLL8,H)4QD\X((&>#PPQG-`&')\4K?3[:6[U32[B*"
M.*!MMNR2MN82&3`+`D((SGY00`210`G_``M?3K16CU/3;^&=8[B9O+B5D"QF
M4A=^[&]EA<@?[)Z4`377Q6TBQM);BZTO5HA%)Y;H(4=E(:17.%<\(89-QZ8&
M1F@">'XA0WNN6.F6FEW:M->>0[S[%&S;/AUPQR-UNXP<'`)QR,@':4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!@
M>+;KPW;:;;_\)/:PW5I).$ABELFNLR[6(P@5CG:'YQTS32;T1,IQ@N:3LCDO
MMOPJ_P"A:M?_``FI?_C-5[.?8P^MX?\`G7WH[S0QI?\`8=D^B00PZ9-$)K=(
M(O*38_S`A<#&<YZ=Z@Z30H`P-3USP];:Y%I^H@&^,:H&:T=U1)FV!6D"E4#L
MF,$C)4>U`%0_\(#);VD070)8MCK;1JL+Y5#N<1J.N"N2%Z$4`7+7Q!X6MT%I
M!J&GVF_<RP,RPEL#+$(<$C&23CUH`STO_`%ND:0G10ML#>PK#%&<9ZRQA1R>
M.2N3ZT`7)K?PC/I5W%Y6FR6=GB*=(`I\HJ!A"$Y!P`-OI@8H`BM9?!;_`&/R
MX=+MY7C:WMXIX%@E"H0S1B-P&`!P2N..#0!$]_\`#VYCDN9+OPY*@A*O(TD#
M`1NYR"?[I8GV)]Z`)II/`UHEQY[Z#"OD*)MYA4>4V0H;/\)W$#/!W'UH`EBN
M_!UE\T5QHL'V&-)<J\2_9TVE4;_9&UR`>!AB!UH`SHM1^'\]U=P^5HX,4C3R
MR-#&(]T>QC(7QMR#.O).<L<=Z`-=;GPMK5\]BL^DW]X-ERT`:.608`VR%>3P
M"N&]Q0!GVMKX""&UA_L2;[9=N2KO'*TUP&+L.22S!G)Q_#GC`H`?K=[X*TVV
MNEU8:5MM<M-`84E=/.;DF,`M\['GCYJ`'K>>%+'Q,8EM+>WU6.,0FX^PE`J[
M-PC\[;M'R@';NZ#I0!/:7GA*W\N:SN='C\R)ID>%XANC`"LX(ZJ`B@GIA0.U
M`%&UE^'NGRVR6C^'+:12+B!8C`A!?"AUQZ\#(Z\"@"RFI>#KAEOOM&D>9:7+
M()9/+5X9G)!'/*NQSZ$^]`"W_B#PG9Z;+=W-Y826D=WMD,8$P6X7Y^0H.'7;
MN)ZJ%R<8S0!+:V?A?4Y]0AM[#3YW$I^U@6RD,[*5.XXPQP64]>I!H`SK?6_!
MT,%SI:R>;%<7+QSQ302RB1W)#%BP.4X(W?<&,9XQ0!'<7?@!O(MIK/3)09/L
M,:?80ZC;@;>%("`R@9^Z#)C/-`&GJMEX9TFUDO;[2+79*3"QCL/.>3S6^9=J
M*6;<QY&#G/-`#';PC);FXNH--A4?Z2XO(%A=#N+[V5P&4[F+9(!RV>]`"+>>
M"Q<@K<Z&+B-XL8>'<KL6:/W!)=ROKN)'4T`75\4:"0V[6+*-DB,S)+,J,L8.
M"Y5B"%SW/%`$\VN:1;R6<<VJ6<3WO_'LKSJ#/T^YD_-U'3U%`%.#QAX;N6<0
M:Y8R*@C)D6=3'\[,J`/]TDE&&`<\?2@"PWB/0T?8VLV"OY_V;:;E`?-_YY]?
MO?[/6@"%_%OA^+5KC2YM7M8;VW:-)(Y7V8:0$HH)X+$`G:#GVH`6?Q5H5O"D
MS:I;O$]XMCNA;S0L['`C;;G:?7.,=Z`%TGQ1H6N%%TW5+>>1U=UB#;9&57*,
MP0X;;N4C.,<4`5[CQKX>M+V6SGU$)<17`M7C\IR1(4\P#@?W03GIVSF@"6?Q
M=X=M5)GUJSCVE%?=*`8BZEEW_P!S*@D;L4`32>)=$BN&MVU6U,R.$=%E#&,E
M2PWX^Z"JDY.!Q0!%>^+=!T_2H-4FU2%K&=BL4T),RO@$DC9G@!6)/0`$G&*`
M&Q^+M"DF,*WP\S[2+4*T3@M(3@8R.5R"-P^7CK0!9TCQ!I>NVTUQIMT)H86V
MNY1D'0,"-P&5(((8<$'(-`&;;^/O#%U]G\K55/VB3RX]T3KS\F"<K\JGS(\,
M<`[UP3D4`6[7Q9H5Y]F^SZC&XN6E6(X8`^46#GD<`%&Y/!QQF@!\7BGP]/-#
M##KVFR2SH9(D2[C+2*,Y90#R!M;D>A]*`(7\8:`ND/JL>HI<6*2^3YMLC3!G
M[A0@);\,]#Z&@!B>-?#KM*JZFA,<JPGY&^9V8J`O'S?,&!(R`5(.,&@"U;^)
M-'N8;Z9+Y$AL6*W$DP,2)C/.Y@`5X/S#(X//%`$$/C'P[/+<(FLV0%NT2LYN
M$"DR+N3!SSN'3U[=*`+#>(]%2Z%L=4M3+YAB($H.QQC*L1PI^8<'!YH`DN]=
MT?3[A[>\U6RMIXXO.>.:X1&6/.-Y!.0N>,]*`*<?C'P_+>&VBU2WD8+&P='#
M(0ZNRG<,C&$8YZ=.>:`+$/B70;BYMK:#6]/EGNEWV\:72%I5Y&5`.6'RGD>A
M]*`'2^(=$AGN()=8L8YK;_7HUR@:+Y2WS#/R_*I//8$]J`&R>)M`A=TEUS3T
M>-&D=6ND!558JS'G@!@5)[$$4`0?\)CX:$LL?]OZ>#"%,A^TIM3=]T%LX!..
M!G-`%V[UK2K"?R+S4[2WE\IIMDLZHWECJ^"?NCN>E`$,?B30YK>[N(-7LIHK
M.$3W#13J_E1E=P9L$X!7D'N*`*6E^-_#NL6=K<VFI1E+BW>Y4,""L:G#%O[N
M#D<^A]*`+$_BK1K73+/4I;PBTO,>2XB<[@1G)`&0`.22`!WQ0!%;>,M#O!`;
M6ZEG\^7RH_*M97+'&=W"_<P0=_W<<YH`WJ`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`.7\;Z%J6NV>F#2Q:F>SO/M#+<RM&K+Y4B8!5
M6.<R`].U7"7)*YS8JA]8I.E>U_\`,Y?_`(1#QA_SZ:-_X,9?_C%='UGR/&_L
M/_IY^'_!.\\-:;-HWA72-+N&1I[*SAMY&C)*ED0*2,@'&1Z5R'T1J4`<?KF@
M^%;_`,5?:-3N8TU=K17CW,@:**)F+,I(^4'S2&R>0./NY`!DVO@+P;I]GIEQ
M#JXCM7DS;N)8%CN)'&U2N$`+%?E&S!8==QYH`4:7X1OGB:U\;GR)M]I'%;W]
MN5:61<'8=I828*XVD'IV)R`7+?X5:);6ZV\=Y?"W7>1$#$%#,9?F`"#&!/(`
M!@8/(.!0!>L?!GA_2#J5C#+Y<^KDS,-T:281LY7"@D*SYRVXY89/2@#-;3?#
M&LO8//XLENY)YFC7S+J(&]DBDW``;1]QP"!'M'(SD&@"&_\`!GANRN!,OB)M
M.N()8\N\T.8RP@"C##`)^RIC.0<MP>@`-"U^&'A^RU--0A^T"=%B4'*=(RA&
M3MR<^4F<DXP=NW)R`10?"W1[:SDLXM0U06TD$4#Q>>I1A&$&2NW#$B-0001@
MM@#<<@"6WPWT2TDMK>'5+Y9[6!1;CS(BT6/(`D`V<G-NAY!&2W'(``-30_`^
MEZ!>FZM);EI"SN?,=2,ND:-T`_YY*?J3[``&?I_PQTG3;VWN[?4M4$\,YF+^
M>H,G"#:Y"@D?NDR>IP<D[FR`7[WP/IU_J,EY-<W?S3),L2L@2-UDCD)'RY^8
MPH#DG@'&,T`+J?@JQU>[OI+N]O6M;X8FLU9%B8^5Y>[(7?G:>F[&><4`8%U\
M.?"%JMKIMU?2PKY3%86>.-9"&=?,*A`H(-RRX`"G>`5.!@`TX/AQH5EI9LXI
M)XH`K9*^6G5"K'`4`9R3P`,GICB@"K<?##P[K-HQN+JYO()V$L;%HF`0F1MJ
MD)]T^=(0>6&[Y6&!@`V[WPC97N@IH_VJ[@MUE:0F%U!;<6+!@05(^8]1P<$8
M(!H`O)I)@U$7=M>2QAW4SQD!A*JQLH7)&1R0V<YROH30!D-X&MI;IKBXU;4)
MY&N#,2_DY(.,QDB,$I\J]\C:`".<@%FZ\)Q7%\ERFIWUN!>?;'AC\HQR/M4`
M,&0\`)Q@@@DG.<8`)M;\-P:_X?72-0NII$!C9IBD3.[(0065D*')'(VX]A0!
MCW7PVT>]MC#<W%RX^S1VO"PJH1'#H/+""/AAG&W!Z$$<4`.7X;:+'I;:=%->
M10/(&;8Z@E?)2$IG;PI1!G'())!'&`"*[^&.C7AN!+>7_DW"*LD.]#&65@RN
M5*$$@J.#E3CE3DT`69O`=D\^C+#=S6]EIEHUJL"*N95+Q,-S$<#,0R``>>",
M8(!5E^%^B2V4%J;F^5(;.*R!6103$BRH0?EQEEF<$X]"-I&:`&V_PKT*RO!=
MV5Q>VEP+CSC)`Z(S#.?+)"9(SGDY?G[U`&IK7@K3]<FN)+BYNHOM.5F$3*`\
M90(T9RIP&`&2,-QP10`NI^"]-U3P\FBRRW,=NDKS*\3*KAVW\@XQD&0D<=0*
M`$T#P5I_AEYFTRXN8_-"J0Q0@*)99=H^7@$S,/7`&,$9(!6O/AUHE[KT^LRO
M<B[F.6*NH&>,<;>V"!_O-ZT`*OP^TM;GS3=WK*#F.(NFV/*D-CY<G.XDY)P>
MF!Q0!4'PJ\._Z7N^T,+H8DY12049""P4,<[R>2<'&,#B@#3;P>I\/V^CIK>I
MI'#+YIFW1.\G).U@T97;D_="@<"@!UMX.L+7SMMS=/YES'<+N9?W?EN75!A?
MN@D]<GGKTP`3:/X?FT8NJZU>7:2M))*;E(B[NVW#;E1>F#C(/7'0`4`9T7@"
MR$MI+=:IJ-Y);SF;=,T0,OSI(%?8B[@'C1@>O&,[>*`+C>#[!K$6GVB[1!-=
M3!DD"N&G\S?@@<8\UL8Y&!UH`R(?A7H$5I+;/->2Q3)LD#.B[A^^S]U1C/VB
M3ICMC&.0#3;P;&WA^?2#K.HXN)_.FN/W/F2=,J1Y>PJ<`$;>1P>IH`2W\#Z;
M;_;<7%VWVN596W,OR$2F8A<+P#(S,<Y^]@8````O_"$:>=-U2Q-U>&/4""6W
MJ&A"L654PO0,21NW=<'(XH`K-\/K%[=X6U74F\Q51W9XV9AY9C;)*?Q)@'TP
M-NV@".+X9Z)%>PW:SWOFVTBO;_O1^XVL655^7H"S=<DAB"2,``%C7_`MIKMZ
MUXU]<P2EED5%VE%D"[/,P1G=L)7&[;SG;F@"%?AQI(MY('N[YTFR90SI^\<^
M;N<X7@DSOP,#I@#%`%FS\#:?9ZG_`&D;N\GNSY9>25D^=D=W!(50`29#G&!@
M#@=P"MJ'PVT75+^\N[R:[D>[D5W4NF`%.=F=N2I!92"3\KD#`Q@`B3X8Z,DE
M@YN[Y_L,2Q1AWC;=C.224SEB<M@@$@'%`"W7PSTNZFDD.I:G&3*9H?+E0&W)
M:1FV'9G!,TGWB<9XQ@8`)O$?P[TGQ/?)=WUW?+(ENUNH212`K(Z$C<I()$AS
M@\E5SG%`%NU\$Z39WVM7</FI+JRLDQ0JC(&SG:R@-U.<DDCM@<4`+X>\'VGA
MZRTN"*ZN9WT^.5%>5@=_F$%B1VY7@#@4`$OA%'TVRT^+5]0@M;,H41!"0VW.
M-VZ,YSD'Z@8Q0!F1?"[0(;J&ZC:X$\5TUTK_`+OEF(.#\O\`LK\WW^#EN3D`
MZ^SBF@LH(;BX-S/'&JR3,H4R,!RV!P,GG`XH`FH`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`X7Q1\.E\2^+[?6FOA!''836K
M*L(W[F&%(;K@;F[@CL<,:`'R>`)YM'TNPDUC)L)C()!$XWAFW,#^\^;G&-Y;
MI\V\\T`33>!IGU73]2BUN>&ZM[F:>9T0CSA)(K%<!@.%18_FW#;VS@@`JW_P
MU@U+Q)?ZK=7<,D-Z\32V[6N1(L;(RJ_S8;[K#.W.&YSB@!?#7PZ;P_K-MJ#Z
MI'=-#8FT+&TVS296(99RQR!Y7RKCC<>30!F^&_A3<>'9;2XM]>,4]O=32XBM
M]B-&[J=F%91R(T#!@PQPN,*P`-;Q)\.X?$0NBU\MJ]R8S(8H,9(21'Y#`_,L
MI[]L'<"00"'6OA[)K7B6XOS?1VL#6,=K%+''FZ0@3!MK\;!^\4GKNV]L#(!-
MX6^'-GX9\]EN$EE>R%G&ZPE6@7?*[;"S,0#YBC!)_P!6,D]@"C9?"X6=I8Q+
MJD`FLI5>"2*P1/+`D#,%&[@L`RDG/WCVXH`K6_P=M(]%NM/EOXG:5-D;I:LB
MQ`NKNH'F9".00RJR\,0"*`.A;P:UWX4@\.7]S%/96L]L8R\1<RQ1&-BL@8\E
MBKCT`(X.#D`P;'X21Z=J%M>P:Q^\AO7NBLEMYBL6*DMAW.)?DQO'')PHH`J:
M7\'?)TK2(+W4+=);*6*9TM(&2,NB@%P0XS)D?ZPCI_#WH`OVGPJ2UGMIO[52
M1X206:T&7!>)MQ.[_6'R?F?^(NQP,T`#_":!KBPF_MB8?8KIIHP$(V(-@CC4
M!@`%2-4.0006X!.0`;OA;PI+H-]<S3S)(BQQPVP5B=JA$#M@@;2[("5!(XSG
MG@`ZF@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@"I>WD]IY?DZ;<WF[.?(:,;/KO=>OMGI4RD
MULK_`'&]&E"I?FFH^O-K]R94_M>^_P"A<U+_`+^6W_QVHYY?RO\`#_,W^JTO
M^?\`'[I__(&G$[20H[1M$S*"4?&5/H<$C/T)%:+5'')*,FD[^?\`PX^F2<CX
MDU_5]%\06T<'V:73VL;B[DA^S,TS>28\JKAP!N\P<[3C;WSP`<]>_%&]LFDN
MA8Z?-!]E#0Q)J'RSR>:4)CD,>&3`&&XY*CJPH`[+0]=EU70;G4FC13'+,J*H
M/W58A<]23@<X_`4`<AIGQ)U%[32[BZM["[AG;9<36KLBKF>.)63E@V/-&1GL
M>01MH`;:?%B[OM-O;ZV\.QM'9K(TN;\+D`1E""4X!$JD[MNP!L\C%`%BW^)5
M^89+FYT6&*`Q!T!NL&-O*1R'8*04^8GS!T49VF@#/U?XM7EEI%W>06%C&PMR
M\!N;DB)F!D'RL!^]#;`4`";E).10!NZ'X^O==\02Z7%H`@2*Y>)II+Q2-BCD
M[54D/T^0XP&!SS0!GWOQ`UO2KK6)[C2X[BPM7E2W55$/F%)5C'[TR,,#<2Q9
M$V@9Y`-`$=E\4ID:ZDU2PAMED=/LL+W&QQNAA=4.5Y+&1\$==I`'&:`-/3?'
MU]>Z_::?+HD,,$XC)F6]+LHD\[9\OEC/^H.>>-PZT`=U0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
%`4`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
